PROPOSED PLACING OF SHARES IN AHLSELL AB (PUBL)

LAUNCH PRESS RELEASE Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or Republic of South Africa or in any other jurisdiction in which offers or sales would be prohibited by applicable law. This announcement contains inside information. PROPOSED PLACING OF SHARES IN AHLSELL AB (PUBL) 16 May 2017  Keravel S.à r.l., a company indirectly owned by CVC European Equity Fund V and CVC European Equity Tandem Fund (“Keravel”), announces its intention to sell approximately 75 million shares in Ahlsell AB (publ) (the “Company”) (approximately 17.2% of the share capital of the Company) through a placing to institutional investors (the “Placing”). The Company will not receive any proceeds from the Placing. The Placing is being conducted by way of an accelerated bookbuild (the “Placing”), which will be launched immediately following this announcement. Carnegie Investment Bank AB, Goldman Sachs International and Nordea Bank AB (publ) are acting as Joint Bookrunners on the transaction. The Placing Shares, in all respects, rank pari passu with the Company's ordinary shares. The results of the Placing will be announced as soon as practicable after the close of the bookbuild process. The timing for the close of the bookbuild process, pricing and allocations are at the absolute discretion of the Joint Bookrunners and Keravel. Keravel has agreed to a 90-day lock-up period with respect to sales of additional shares of the Company, subject to certain exceptions, including sales and transfers with one or more investors on the basis of individually negotiated agreements. The distribution of this announcement and the offer and sale of the Placing Shares in certain jurisdictions may be restricted by law. The Placing Shares may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the Placing Shares in such jurisdiction. No action has been taken by Keravel, the Joint Bookrunners or any of their respective affiliates that would permit an offering of the Placing Shares or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. This announcement is not for publication, distribution or release, directly or indirectly, in or into the United States of America (including its territories and dependencies, any State of the United States and the District of Columbia), Australia, Canada, Japan or Republic of South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No prospectus or offering document has been or will be prepared in connection with the Placing. Any investment decision to buy securities in the Placing must be made solely on the basis of publicly available information. Such information is not the responsibility of and has not been independently verified by Keravel, the Joint Bookrunners or any of their respective affiliates. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither this document nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy securities in the United States. There will be no public offer of any securities in the United States or in any other jurisdiction. In member states of the European Economic Area (“EEA”) which have implemented the Prospectus Directive (each, a “Relevant Member State”), this announcement and any offer if made subsequently is directed exclusively at persons who are ‘qualified investors’ within the meaning of the Prospectus Directive (“Qualified Investors”). For these purposes, the expression ‘Prospectus Directive’ means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in a Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression ‘2010 PD Amending Directive’ means Directive 2010/73/EU. In the United Kingdom this announcement is directed exclusively at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) who fall within Article 49(2)(A) to (D) of the Order, and (iii) to whom it may otherwise lawfully be communicated. Goldman Sachs International, Carnegie Investment Bank AB and Nordea Bank AB (publ) are acting for Keravel only in connection with the Placing and will not will not be responsible to anyone other than Keravel for providing the protections offered to the respective clients of the Joint Bookrunners, nor for providing advice in relation to the Placing or any matters referred to in this announcement. This announcement is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in the United States, Canada, Australia, South Africa, Japan or any jurisdiction where such offer or solicitation would be unlawful. No action has been taken that would permit an offering of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

Resolutions at Precise Biometrics’ annual general meeting 2017

ELECTION OF BOARD MEMBERS, CHAIRMAN OF THE BOARD AND AUDITORIn accordance with the Nomination Committee´s proposal, the AGM resolved to re-elect Anna Almlöf, Torbjörn Clementz, Torgny Hellström, Matts Lilja, Mats Lindoff and Synnöve Trygg as Board members. Torgny Hellström was re-elected as Chairman of the Board.The accounting firm EY was re-elected as auditor of the company for a mandate period of one year, with the authorized public accountant Johan Thuresson as auditor in charge.In accordance with the Nomination Committee’s proposal, the AGM resolved on fees entailing that the Chairman of the Board shall receive SEK 545,000, that each of the other five members of the Board shall receive SEK 190,000 and that remuneration for committee work shall amount to SEK 35,000 for members of the Audit Committee, SEK 70,000 for the Chairman of the Audit Committee and SEK 25,000 for members and Chairman of the Remuneration Committee.DIVIDENDSIt was resolved that no dividends should be paid for the financial year of 2016.GUIDELINES FOR REMUNERATION TO SENIOR MANAGEMENTIn accordance with the proposal of the Board, the AGM resolved to adopt guidelines for remuneration to senior management principally entailing that remuneration and terms of employment shall be competitive and in accordance with market conditions. In addition to fixed salary, management may also receive variable salary, which shall be based on the group’s result and individual goals. The variable part of the salary may amount to a maximum of 75% of the fixed salary for the managing director and 50% of the fixed salary for the other members of senior management. Remuneration may also be paid by way of warrants and other share-related incentive programs.AUTHORIZATION FOR THE BOARD TO RESOLVE UPON NEW ISSUES OF SHARES AND/OR CONVERTIBLESIn accordance with the proposal of the Board, the AGM resolved to authorize the Board to decide on new issues of shares and/or convertibles. Such issue may entail a deviation from the shareholders' preferential right for payment in cash, in kind and/or through set-off. The issue may result in an aggregate increase in the share capital corresponding to the issue of a maximum of 36,023,146 shares and/or convertibles to be converted into a maximum of 36,023,146 shares. Full exercise of the authorization, and where applicable full conversion, is equivalent to a dilution of approximately 10% of the current share capital and votes. The purpose of the authorization and the reason for the deviation from the shareholders’ preferential right is to enable the company, by way of issues of new shares/convertible bonds for payment in cash, in kind or through set-off, to strengthen the company’s capital base in connection with company acquisitions or strategic capital or other investments, and to obtain capital contributions from new owners that are considered strategically important from an operational, financial, structural or other perspective.RESOLUTION REGARDING INCENTIVE PROGRAM FOR THE COMPANY’S EMPLOYEESIn accordance with the proposal of the Board, the AGM resolved to adopt a three year incentive program for the company’s employees by way of issue of a maximum of 5 million subscription warrants, entitling to subscription for the equivalent number of shares during the period from and including 1 June 2020 up to and including 30 June 2020. The subscription price per share shall correspond to 200% of the volume weighted mean value according to Nasdaq Stockholm’s official price list for share in the company during the period from 17 May 2017 up to and including 31 May 2017. The subscription warrants shall be directed to a wholly-owned subsidiary of the company, which in turn shall transfer the subscription warrants to the company’s employees at market value in accordance with specified allotment conditions. Assuming that all 5 million subscription warrants are exercised to subscribe for new shares, the company’s share capital will increase with a maximum of SEK 150,000, which would result in a dilution of approximately 1.4% in relation to the company’s current share capital.FOR FURTHER INFORMATION, PLEASE CONTACTHåkan Persson, CEO, Precise Biometrics ABPhone: +46 46 31 11 05 or +46 734 35 11 05E-mail: hakan.persson@precisebiometrics.comABOUT PRECISE BIOMETRICSPrecise Biometrics is a market leading supplier of solutions for convenient and secure authentication of people’s identity. We develop and sell fingerprint software and mobile smart card readers that provide the market’s best user experience and security. Our solutions are used hundreds of millions of times every day by people all over the world and are marketed together with strong business partners. For more information, please visit; www.precisebiometrics.com. Follow us on LinkedIn  and Twitter .  

Bulletin from Moberg Pharma’s AGM 2017

Adoption of the income statements and the balance sheetsThe Annual General Meeting (the “Meeting”) approved the income statements and the balance sheets for the fiscal year 2016. The Meeting resolved, in accordance with the proposal of the Board of Directors, that no dividend should be paid for the fiscal year 2016. The Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year 2016. Board of DirectorsIn accordance with the proposal of the Nomination Committee, the Meeting resolved that the Board of Directors shall consist of six persons and no deputies. The Meeting resolved re-election of the Board Directors Thomas Eklund (Chairman), Torbjörn Koivisto, Geert Cauwenbergh, Thomas B. Thomsen and Mattias Klintemar, and election of Sara Brandt as new member, until the end of the next Annual General Meeting. Wenche Rolfsen chose, after seven years as Board Director, to resign.   The Meeting resolved, in accordance with the proposal of the Nomination Committee, that an aggregate fee to Board members of SEK 1,350,000 shall be paid to the Board Directors, of which SEK 360,000 to the Chairman and SEK 170,000 for all other Board Directors elected by the Annual General Meeting. An additional fee of SEK 60,000 shall be paid to the members of the Compensation Committee, SEK 30,000 to the chairman and SEK 15,000 to the other members (2). A fee of SEK 80,000 shall be paid to the members of the new Audit and Finance Committee, SEK 40,000 to the chairman and SEK 20,000 to the other members (2). Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice. Nomination CommitteeThe Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of four members. The Nomination Committee shall comprise one representative of each of the three largest shareholders or owner groups in the Company in terms of votes as per September 30, 2017, besides the Chairman of the Board of Directors. Principles for remunerationThe Meeting resolved to approve the Board of Director’s proposal for principles of remuneration to senior executives in Moberg Pharma. Amendment of the Articles of Association regarding the share capital and number of sharesThe Board of Directors proposes that the Annual General Meeting resolves to amend §4 of the Articles of Association to “The share capital shall be not less than SEK 1,700,000 and not more than SEK 6,800,000”, and to amend §5 of the Articles of Association to “The number of shares shall be not less than 17,000,000 and not more than 68,000,000.”. Employee Stock Option Plan 2017In accordance with the Board of Directors’ revised proposal, the Meeting resolved to adopt an employee stock option plan for employees and consultants in the Company and in the Company’s wholly-owned subsidiary Moberg Pharma North America LLC. It will be permissible to allot a maximum of 75,000 employee stock options per plan participant and a maximum of total 413,500 employee stock options. The participants in the program are divided in two categories: the senior executives’ (Anna Ljung, Martin Ingman, Kjell Rosenfeldt, Jeff Vernimb and Peter Wolpert) (“Group 1”) and other participants (“Group 2”). The Board of Directors and the Chief Executive Officer shall decide which persons shall be encompassed in Group 2 based on position, qualification and individual performance. The participants in Group 1 and 2 are jointly referred to as “Participants”. Within Group 1, Anna Ljung and Martin Ingman are proposed to be allotted 30,000 employee stock options each, Kjell Rensfeldt is proposed to be allotted 45,000 employee stock options, Jeff Vernimb is proposed to be allotted 62,000 employee stock options and Peter Wolpert is proposed to be allotted 55,000 employee stock options. The number of employee stock options to be allotted to Group 2 participants will be resolved by the Board of Directors and the Chief Executive Officer and may be adjusted proportionally based on each person's time as an employee or as a consultant in the Company or Moberg North America. Participants in the Program shall be allotted the employee stock options free of charge. In order to secure the Company’s commitments under the employee stock option plan, the Meeting resolved on an issue of a maximum 413,500 warrants to the Company’s wholly-owned subsidiary Moberg Derma Incentives AB. In addition, the Meeting resolved to approve that the subsidiary is entitled to transfer warrants or shares in the Company to the Participants, or otherwise dispose of the warrants, in order to secure the Company’s commitments and costs in connection with the employee stock option plan. In the event that all warrants issued in respect of Employee Stock Option Plan 2017 are used to subscribe for new shares, the Company’s share capital will increase by SEK 41,350 from SEK 1,741,184.20 to SEK 1,782,534.20. This is equivalent to a dilution of approximately 2 per cent of the shares and votes in the Company. Authorization to issue shareThe Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders’ preferential right, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company’s share capital by issuing new shares in the Company. The total number of shares issued in accordance with this authorization may be equivalent to a maximum of 20 per cent of the shares in the Company at the time of the 2017 Annual General Meeting. About this informationMoberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 pm (CET) on May 16th, 2017.

Promore Pharma AB files phase III clinical trial application in India

The company announced the filing with Drugs Controller General in India of a clinical trial application for a randomized double blinded clinical study with patients undergoing tendon repair surgery after accidental flexor tendon transection. The filing is part of a multi-national clinical trial that aims at enrolling up to 600 patients. This filing is a direct result of the successful completion of a Phase IIb clinical trial on PXL01 of the same indication. Later in 2017, the company is aiming to submit filings in additional countries, in the EU under the same protocol. “This marks a significant milestone in our PXL01 development initiative,” said Jonas Ekblom, CEO of Promore Pharma. “This has been a highly collaborative partnership since its inception, and I want to recognize the tremendous work of all parties involved, including the teams of our strategic alliance partners PharmaResearch Products Ltd, and the Technomark Group”, he continued. Promore Pharma is developing two pharmaceutical products, both in late stage clinical development for the bioactive wound care market. PXL01 is a human therapeutic peptide for prevention of post-surgical adhesions after tendon repair surgery in the hand, lower arm and foot. Postoperative adhesions constitute a substantial clinical problem after most surgical procedures, but in particular hand surgery. Flexor tendon injury and repair result in adhesion formation around the tendon, which restricts the gliding function of the tendon, leading to decreased digit mobility and impaired hand recovery, with reduced sensitivity and pain as a consequence Small decreases in mobility greatly impact the quality of life due to difficulties in performing easy tasks, such as closing buttons or using a key board. PXL01 is a synthetic peptide sequentially derived from human lactoferrin, an iron-binding glycoprotein present in milk and mucosal secretions, which exhibits antimicrobial and anti-inflammatory properties. The company also announced in April that it is currently planning for an initial public offering at Nasdaq First North in Stockholm later in 2017 to broaden its shareholders base. The current main owners are Midroc New Technology AB, Rosetta Capital and PharmaResearch Products Ltd. ### About Promore Pharma (www.promorepharma.com) Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need. Promore Pharma has two projects, PXL01 and LL-37, in late stage clinical phase. PXL01, that will be used to prevent post-surgical adhesions and scars, is being prepared for clinical phase III-studies on patients performing tendon repair surgery in the hand and LL-37 is prepared for a clinical phase IIb study on patients with venous leg ulcers. The product candidates can also be envisioned for other indications, such as preventing dermal scarring and treatment of diabetic foot ulcers. Rosetta Capital, Midroc New Technology and PharmaResearch Products Ltd are the main investors in Promore Pharma. 

Nitro Games releases Medals of War for an exclusive launch in Sweden!

On this date, Nitro Games released an early stage test version of the upcoming game, Medals of War in Sweden. The purpose of the limited launch is to gather actual player feedback and preferences to fine-tune the development of the title. This market test release is a part of Nitro Games’ MVP process, where game development is closely tied to actual market data and early-stage qualitative community feedback. Experience WW2 Fantasy! The game takes place in Warland, a world with units, weapons, equipment and environment inspired by the actual era. Warland comes alive with explosive effects, outstanding graphics and awesome sounds! Collect – Control - Compete! The Player’s army is formed of several heroic units of various different types, such as Riflemen, Grenadiers and Tanks. Players get to choose special Commands to aid their Units in battle - everything from a Napalm Strike to First Aid! All units and Commands are upgradeable and have unique role in the battlefield. Players are matched with each other in intense PvP combat – In real-time! Medals of War is a community-focused game that brings players together with their friends. The aim is to level up, hone your skills to be the best commander in Warland. "With Medals of War we're bringing explosive, easy to pick-up PvP action to mobile devices in an immersive WW2-inspired Warland universe. Based on our previous experience, Sweden is a fitting choice for an early stage release, since as a market it reflects the wider western markets well.” - Henri Lindgren, Executive Producer of Medals of War at Nitro Games Plc. Find out more and follow us on: Facebook: https://www.facebook.com/MedalsofWar   Twitter: https://twitter.com/MedalsofWar  Website: www.medalsofwargame.com 

Catena Media – interim report Q1 2017

Continued strong growth First quarter of 2017 · Revenues totalled EUR 15.23 million (7.46), an increase of 104 percent compared with the same quarter for the previous year. · Operating profit increased to EUR 6.64 million (3.18) corresponding to an operating margin of 44 percent (43). Adjusted operating profit excluding non-recurring IPO expenses, which during this quarter related to the listing on Nasdaq Stockholm, amounted to EUR 6.99 million (4.16), corresponding to an adjusted operating profit margin of 46 percent (56).  · EBITDA increased to EUR 7.22 million (3.34) corresponding to an EBITDA margin of 47 percent (45). Adjusted EBITDA excluding non-recurring IPO expenses, which during this quarter related to the listing on Nasdaq Stockholm, amounted to EUR 7.56 million (4.32), corresponding to an adjusted EBITDA margin of 50 percent (58). · New depositing customers (NDCs) totalled 80,421 (32,321), an increase of 149 percent compared with the same quarter for the previous year and an increase of 20 percent when compared to the previous quarter. · Earnings per share amounted to EUR 0.083 (0.074) before dilution.  · Earnings per share amounted to EUR 0.082 (0.073) after dilution.  Significant events during and after the quarter ·  In January Catena Media continued to strengthen the management team through recruitments to a number of key positions. Johannes Bergh was recruited as Chief Operating Officer (COO) and Claes Wenthzel was recruited as the new Group Chief Financial Officer (CFO). Claes Wenthzel has extensive experience in similar roles at several mid-sized listed companies.  ·  In January, 440,669 new shares in Catena Media plc were issued to be utilised as part of the settlement of the first instalment due for the US asset acquisition which was finalised in the previous quarter. Revenues from the US acquisition are reflected in Catena Media’s revenues and results as from 16 January 2017.  · On 10 February Catena Media acquired the assets of the Swedish focused casino affiliate, Slotsia.com. The purchase price comprised a first instalment of EUR 3.58 million. Additional earn-out payments can amount to a maximum of EUR 5 million, and are based on the revenue performance over a period of two years. · Furthermore, Catena Media has continued with its preparations for a move from Nasdaq First North Premier to Nasdaq Stockholm’s main list (Mid Cap). · On 30 March 2017, Catena Media secured a long-term cooperation with SBAT founder Gary Gillis whereby the original earn-out agreement was amended and replaced by an immediate and final payment of EUR 3.25 million as settlement for the asset acquisition.  Following the amendment to the acquisition agreement, the SBAT founder entered into an employment agreement with Catena Media. · In May, Catena Media bought the assets of Online Media, a UK-based, fast-growing sports betting affiliate with a strong position within display marketing. The acquired assets have a running rate of sales of about EUR 300,000 per month and a pre-tax profit margin of more than 70%. · On 16 May, Catena Media announced that the company was exploring the possibility of making a tap issue in an amount of EUR 50.0 million under the company’s outstanding maximum EUR 100.0 million senior secured callable floating rate bonds issues due in 2019 with ISIN SE0008964720. The proceeds from the potential tap issue are intended to be used for acquisitions. Comment from Robert Andersson, CEO Continued strong growth  Catena Media continued its strong growth in the first quarter of 2017 and revenues amounting to record breaking EUR 15.23 million, up 104% when compared to the same quarter of the previous year. NDC numbers were also at an all-time high reaching 80,241 for the quarter, an increase of 149% compared to the same quarter of the previous year. The operating profit was up 109% in the first quarter of 2016, corresponding to EUR 6.64 million.    The first quarter of the year is seasonally strong and we are pleased to note stable growth numbers in our existing assets. AskGamblers is a great example of assets which we acquired early last year and which have trended very positively since. Overall, the first quarter was primarily characterised by the successful integration of our US operation, several ongoing negotiations in multiple markets and the acquisition of the casino affiliate Slotsia.com. We were also pleased to reach a new agreement with the founder of SBAT that replaced the former earn-out agreement with an immediate and final payment as settlement for the asset acquisition. The fast pace of growth has also given us a delicate problem of outgrowing our office space in London, Malta and Serbia. We have therefore moved our offices in London and Serbia during the first quarter and will move in Malta during the third quarter. We have also expanded our efforts in Budapest where we have our outsourced technology teams. As a consequence of our current M&A pipeline in combination with strategic initiatives, the Board of Directors has decided that the move to the Nasdaq Stockholm main market would be best suited to H2 2017. The decision enables us to keep a clear focus on the business and our growth strategy, while we make sure to utilise the opportunities ahead. The company has made most of the necessary preparations already and is well prepared for the move. Focusing on revenue share for Paid mediaDuring the quarter, we took a strategic decision to shift Paid media revenue toward a revenue share model which will increase the life-time revenues from customers, as opposed to upfront payments typical of the Paid media approach. Moreover, revenue share models are more profitable over time and contribute to building strategic value. Therefore, we have taken a decision to accelerate the shift in Paid media towards revenue share at a faster pace than originally planned. This had a negative impact on the operating margin in the first quarter and is also expected to impact the second quarter. In recent years, we have made several acquisitions that have impacted our intangible assets, this has resulted in increased depreciation compared to the previous quarters. This resulted in an increase in the ratio between EBITDA and EBIT. The company therefore intends to place more emphasis on operating income before depreciation, as it gives a more accurate picture of the company's development. Catena Media will continue its solid growthAfter the start of May 2017, we acquired Online Media in the UK. The transaction strengthens our offering in sports betting and broadens the existing media offering to customers through the addition of alternative display marketing. Consolidation in the affiliate market has increased during the last quarters; Catena Media wants to capture a leading role and is predominantly focussing on larger assets since we are well positioned to capitalise on the growing market. With our dedicated team, we will continue to build Catena Media’s solid growth story. Based on the company’s acquisition agenda, the Board has decided to investigate the possibility of utilising the remaining bond volume within the existing bond framework. For further information, please contact: Robert Andersson, CEOPhone: +356 770 329 28E-mail: robert@catenamedia.comwww.catenamedia.com This information is information that Catena Media p.l.c is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 17 May, 2017 at 07.00 CET. About Catena Media Catena Media is a fast-growing online performance marketing and lead generation company within iGaming with portals like AskGamblers  and RightCasino . The Group has established a leading market position through strong organic growth and acquisitions in its core markets. Catena Media was listed on Nasdaq Stockholm First North Premier in February 2016. By the end of 2016, the company’s revenues reached more than EUR 40 million on a yearly basis. The Group was founded in 2012 and has today about 200 employees. The Group Head Office is situated in Malta. The company’s certified advisor is Avanza.

Ambea’s Quality Report for first quarter 2017

”Customer and user surveys are crucial for developing health and social care. Not only the survey and the questions asked, but also that the results can be compared to other similar operations all over Sweden. Then we learn from and get inspired by each other, regardless of if we are private or public providers. Therefore we hope that The National Board of Health and Welfare (Socialstyrelsen), in cooperation with The Swedish Association of Local Authorities and Regions (SKL) and The Association of Private Care Providers (Vårdföretagarna) continue to develop Open comparison in elderly care, the LSS-legislation (the Swedish Act Concerning Support and Service for Persons with Certain Functional Impairments) as well as for the Individual and Family care area”, says Lena Freiholtz, Ambea’s Quality and Sustainability Director. Highlights in the Quality Report for the first quarter: »            Vardaga’s elderly care services and Nytida’s LSS operations have been quality declared according to the Association of Private Care Providers’ concept. »            The projects concerning language and work training, education and employment of newly arrived people continue, now in cooperation with the employment service. »            Nytida presents a new educational framework, which was rolled out during the spring. »            Vardaga introduces MedView to improve the structure for medication of the elderly and increased quality of life for the residents. »            The number of reported deviations increased from 8,027 to 10,122, a clear indication of satisfactory implementation of new operations in the use of the management system. »            Of a total of 10,122 deviations, a degree of seriousness of 3 accounted for 0.88 per cent and a degree of seriousness of 4 accounted for 0.12 per cent. »            Three reports according to Lex Sarah, of which, two in Nytida and one in Vardaga. »            One Lex Maria report, in Vardaga. For more information, please contact: Lena Freiholtz, Quality and Sustainability Director Telephone: +46 733 77 55 50 E-mail: lena.freiholtz@ambea.se  Nanna Wedar, Head of Communication Telephone: +46 70 166 58 88 E-mail: nanna.wedar@ambea.se Ambea is present within care services and has around 14,000 employees. Ambea offers services within disabled care, individual and family care and elderly care, with a focus on residential care and own management. We strive to be the quality leaders in all we do – and our vision is to make the world better, one person at a time. As of December 31, 2016, Ambea had approximately 6,200 beds and 1,300 school-/daily activity-placements in around 460 units across Sweden and Norway. Total sales and adjusted EBITA for the 2016 financial year amounted to SEK 5,409 million and SEK 456 million. The company was founded in 1996 and its head office is located in Solna, Sweden. Ambea is listed on Nasdaq Stockholm. www.ambea.com

Sweco advices in power plant project in Rwanda to double national energy supply and reduce costs

The new peat power plant, located close to the Akanyaru river in southeast of Rwanda, will increase the country’s electricity production by 80 MW while reducing production costs and harmful emissions. The peat will be transported from near-by peat bogs and replaces, as a domestic energy source, other resources such as imported oil. The power plant will in total reduce energy production costs with up to 40 percent. The peak demand of electricity in Rwanda is currently 115 MW. Energy experts from Sweco  in Sweden and Finland have been involved throughout the process and have conducted feasibility studies for the power plant and peat production. Sweco will continue to assist the project by overseeing project compliance during the construction period. “This is a project of major significance for Rwanda. We are excited to be able to assist with our expertise. Rwanda has accomplished an important and impressive progress during the last two decades. This power plant will be a great contribution in fulfilling the country’s ambitious plans to expand its energy supply”, says Åsa Bergman, President of Sweco Sweden. “The supply of efficient energy is crucial to support economic growth. This project has been developed in cooperation between Finnish and Swedish specialists during the last 4 years and we are happy to be able to assist with our energy expertise going forward”, says Markku Varis, President of Sweco Finland. In earlier stages of the project, Sweco has prepared technical specifications for the turn-key EPC contract (Engineering Procurement Construction), and has assisted throughout the procurement process. Sweco will be on site to ensure that the project’s implementation is carried out as agreed in the contract. The project is set to be finished in 2020. Finnish suppliers have been selected for vital parts of the plant with support from Finnish export funds. The project is sponsored by the Turkish energy company Hakan Madencilik A.S, and U.K based Quantum Power, a power and energy infrastructure investment platform. Project development manager since 2013 is Themis Infra.

Paradox Interactive Opens New Studio for Mobile Game Development

STOCKHOLM — May 17, 2017 — Paradox Interactive, a global developer and publisher of games on all platforms, today announced the opening of a new studio which will focus on mobile game development. The new studio will operate in Malmö, a city in southern Sweden, and will consist of a small team of experienced developers focused on bringing mobile gamers the kind of deep, challenging experiences the world has come to expect from Paradox.Paradox’s new studio will join the city’s rapidly growing development community, working alongside such peers as Massive Entertainment and Tarsier Studios.“Paradox is committed to exploring new territory in mobile game development, and I’m eager to lead that charge,” said Kim Nordström, SVP of Innovation and Mobile at Paradox Interactive. “Our plan is to  bring the iconic Paradox style to mobile players across a broad catalog of titles. To achieve that, it's important that we bring aboard the right people – people capable of delivering the kind of hardcore strategic titles we’re known for on PC. Games like Prison Architect: Mobile are just the beginning!”“We chose Malmö because it has such a vibrant development community, and we know there’s plenty of talent to be found here,” said Susana Meza Graham, COO at Paradox Interactive. “In the coming months we are looking to add several new members to the team, both in Malmö and the mobile publishing team in Stockholm.”For more information on how to join the Paradox mobile team, please visit http://career.paradoxplaza.com/departments/mobile .

Alimak Group signs new construction order with Canary Wharf Contractors to a value of approximately SEK 55 million in the UK

Alimak Group, market leaders in vertical access solutions, has been awarded the contract to provide equipment and services on the flagship 57-story residential skyscraper in the new Wood Wharf development in Canary Wharf, London. The project will run until 2020 with most of the equipment being delivered during 2017. The order includes high performance Construction Hoists with related services for the vertical access systems during the project. “This is the third large order we have received from the Canary Wharf Group recently in London and we are proud to extend our partnership on this project. The new Wood Wharf development of office and retail space is very exciting and we are very pleased to see a continued interest in our solutions that are built to support safe and reliable vertical access during the construction period”, says Tormod Gunleiksrud, CEO, Alimak Group. For further information, contact: Per Ekstedt, CFO, Phone: +46 8 402 14 57 Sofia Wretman, Head of Communications & IR, Phone: +46 8 402 14 40 This information is information that Alimak Group AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 17 May 2017. About Alimak Group Alimak Group is a world-leading provider of vertical access solutions for industrial and construction industries. With presence in more than 100 countries, Alimak develops, manufactures, sells and provides service to vertical access solutions with focus on adding customer value through greater safety, higher productivity and improved cost efficiency. The Group´s products and solutions are sold under the brands Alimak Hek, CoxGomyl, Manntech and Avanti. Alimak has an installed base of more than 60,000 elevators, hoists, platforms, service lifts and building maintenance units around the world. Founded in Sweden 1948 Alimak has its headquarters in Stockholm, 12 manufacturing facilities in 8 countries and 2,400 employees around the world. www.alimakgroup.com 

Proact selected to provide operational and strategic IT services to UK public sector

As a supplier to ESPO, a local authority owned purchasing and supply consortium, Proact will be able to provide its proven IT services to all UK public sector bodies, including (but not limited to) central government departments and agencies, NHS, local authorities, police and emergency services, higher and further education, schools and academies and HSC bodies. Utilising Proact’s successful heritage of delivering IT infrastructure projects, the solutions provider is proud to continue its support for UK public sector organisations, delivering exceptional advice and services to help IT departments tackle a variety of real-world issues. Proact was able to meet the stringent credentials required to be part of this framework which is compliant with UK/EU procurement legislation. Service providers on the framework had to be assessed during the procurement process, proving their financial stability, track record, experience and technical and professional ability. Proact was able to demonstrate all of these criteria and will adhere to pre-agreed terms and conditions which will underpin all engagements. Having worked with numerous public sector organisations, including NHS Trusts and government departments, Proact has proven its ability to design, build and deliver successful IT transformations, helping resolve key customer challenges with access to high quality IT consultancy services around complex requirements including cloud and data centre solutions, data protection and cyber security, disaster recovery and digital strategy development. Proact’s inclusion in the framework will provide customers with quick and simple access to leading IT services, allowing them to save valuable time and resources through greatly reduced procurement timescales. The framework also intends to make procuring consultancy services more cost-effective and is free to use for customers. Jason Clark, CEO and President at Proact, says: “We are delighted to have been selected as a supplier which will allow us to continue to support public sector organisations across the UK in meeting their regulatory and policy challenges in designing and building world class and transformative digital infrastructure and public services.”

Hoist Kredit AB (publ) announces final results of its tender offer for its outstanding SEK notes

Tender Offer regarding the Company’s outstanding Notes Hoist Kredit AB (publ) (the “Company”), a wholly-owned subsidiary of Hoist Finance AB (publ), today announces the final results of its invitation to all holders of the outstanding SEK 350,000,000 fixed term subordinated loan notes due 2023 (ISIN SE0005280591) (the “Notes”) to tender any and all such Notes for purchase by the Company for cash, subject to the terms and conditions described in the consent solicitation and tender offer memorandum dated 27 April 2017 (the “Consent Solicitation and Tender Offer Memorandum”) (the “Tender Offer”). At the Tender Deadline (as defined in the Consent Solicitation and Tender Offer Memorandum) at 5:00 p.m. CET on 10 May 2017, valid tender instructions of SEK 287,000,000 in aggregate principal amount of Notes had been received pursuant to the Tender Offer. The Company hereby announces that the New Issue Condition (as defined in the Consent Solicitation and Tender Offer Memorandum) has been satisfied and that it has decided to accept for purchase all validly tendered Notes. The Tender Consideration (as defined in the Consent Solicitation and Tender Offer Memorandum) for the Notes repurchased by the Company is 114.5 per cent. of the nominal amount of the Notes. The Company will pay accrued and unpaid interest on Notes accepted for purchase in the Tender Offer. The expected settlement date for the Tender Offer is 23 May 2017. All Notes purchased by the Company will be cancelled. Effective Date for amendments to the terms and conditions of the Notes and Extraordinary Early Redemption of the outstanding Notes The Company today also announces that the amendments to the terms and conditions of the Notes set out in the Proposal (as defined in the Consent Solicitation and Tender Offer Memorandum) shall become effective on 18 May 2017, that the Extraordinary Early Redemption (as defined in the Consent Solicitation and Tender Offer Memorandum) will be made on 30 May 2017 and that the Early Consent Fee (as defined in the Consent Solicitation and Tender Offer Memorandum) will be paid to the direct registered noteholders and nominees who have submitted valid consent voting instructions in favour of the Proposal before the Early Consent Fee Deadline (as defined in the Consent Solicitation and Tender Offer Memorandum). All outstanding Notes that are not repurchased pursuant to the Tender Offer will be redeemed at an early redemption price of 112 per cent. of the nominal amount (together with accrued and unpaid interest) of each Note. The Company will pay an Early Consent Fee (as defined in the Consent Solicitation and Tender Offer Memorandum) of 2.5 per cent. of the nominal amount of the Notes in respect of which noteholders delivered a valid voting instruction in favour of the Proposal before the Early Consent Fee Deadline (as defined in the Consent Solicitation and Tender Offer Memorandum). No Early Consent Fee will be payable in respect of Notes validly tendered pursuant to the Tender Offer. The details for the Tender Offer and the consent solicitation are fully described in the Consent Solicitation and Tender Offer Memorandum. Dealer Managers and Solicitation Agents: Deutsche Bank AG, London Branch: +44 20 7545 8011, liability.management@db.com Nordea Bank AB (publ): +45 5547 4294, bibi.larsen@nordea.com / NordeaLiabilityManagement@nordea.com  Tender and Paying Agent: Nordea Bank AB (publ): IssuerSeCustodian@nordea.com For further information, please contact: Magnus Linnersand, Group Head of Treasury Telephone: +46 (0)8 555 177 72 Michel Jonson, Group Head of Investor Relations Telephone: +46 (0)8 555 177 19 The information above has been published pursuant to the Swedish Securities Markets Act (Sw. lagen om värdepappersmarknaden) and/or the Swedish Financial Instruments Trading Act (Sw. lagen om handel med finansiella instrument). This information was released for publication at 08:00 CET on 17 May 2017. 

RESULTS OF PLACING OF SHARES IN AHLSELL AB (PUBL)

PRICING PRESS RELEASE Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, Japan or Republic of South Africa or in any other jurisdiction in which offers or sales would be prohibited by applicable law. RESULTS OF PLACING OF SHARES IN AHLSELL AB (PUBL) 17 May 2017  Following the press release issued yesterday, Keravel S.à r.l., a company indirectly owned by CVC European Equity Fund V and CVC European Equity Tandem Fund (“Keravel”), has successfully completed the sale of 90 million shares equal to 20.6% of the share capital of the Company (the “Offering”). The Company will not receive any proceeds from the sale. Following the placement Keravel holds 173,402,320 shares of the Company, equal to 39.7% of the share capital of the Company. The Offering, carried out through an accelerated bookbuilding, was priced at SEK 58.50 per share and will be settled by delivery of shares and payment of the consideration on 19 May 2017. Keravel has agreed to a 90-day lock-up period with respect to sales of additional shares of the Company, subject to certain exceptions, including sales and transfers with one or more investors on the basis of individually negotiated agreements. Carnegie Investment Bank AB, Goldman Sachs International and Nordea Bank AB (publ) acted as Joint Bookrunners in the Offering. The distribution of this announcement and the offer and sale of the Placing Shares in certain jurisdictions may be restricted by law. The Placing Shares may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the Placing Shares in such jurisdiction. No action has been taken by Keravel, the Joint Bookrunners or any of their respective affiliates that would permit an offering of the Placing Shares or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. This announcement is not for publication, distribution or release, directly or indirectly, in or into the United States of America (including its territories and dependencies, any State of the United States and the District of Columbia), Australia, Canada, Japan or Republic of South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No prospectus or offering document has been or will be prepared in connection with the Placing. Any investment decision to buy securities in the Placing must be made solely on the basis of publicly available information. Such information is not the responsibility of and has not been independently verified by Keravel, the Joint Bookrunners or any of their respective affiliates. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither this document nor the information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy securities in the United States. There will be no public offer of any securities in the United States or in any other jurisdiction. In member states of the European Economic Area (“EEA”) which have implemented the Prospectus Directive (each, a “Relevant Member State”), this announcement and any offer if made subsequently is directed exclusively at persons who are ‘qualified investors’ within the meaning of the Prospectus Directive (“Qualified Investors”). For these purposes, the expression ‘Prospectus Directive’ means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in a Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression ‘2010 PD Amending Directive’ means Directive 2010/73/EU. In the United Kingdom this announcement is directed exclusively at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) who fall within Article 49(2)(A) to (D) of the Order, and (iii) to whom it may otherwise lawfully be communicated. Goldman Sachs International, Carnegie Investment Bank AB and Nordea Bank AB (publ) are acting for Keravel only in connection with the Placing and will not will not be responsible to anyone other than Keravel for providing the protections offered to the respective clients of the Joint Bookrunners, nor for providing advice in relation to the Placing or any matters referred to in this announcement. This announcement is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in the United States, Canada, Australia, South Africa, Japan or in any jurisdiction where such offer or solicitation would be unlawful. No action has been taken that would permit an offering of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

Volati acquires Akademibokhandeln and Bokus

Akademibokhandeln is the market leading book retailer in Sweden with a market share of about 35% of consumer book retailing and has a strong offering for all product and delivery formats. With 108 stores nationwide, 80 under its own management and 28 run as franchises, together with online sales under the Akademibokhandeln and Bokus brands, the company operates modern and profitable sales channels focused on consumers, companies and public sector operations. With its vision of conveying “the joy of reading to everyone, every day” Akademibokhandeln also wants to be a hub for culture and a meeting place for literature. For 2016, the Akademibokhandeln Group’s net sales amounted to SEK 1.8 billion and EBITDA to SEK 125 million. “We are extremely pleased and proud to be able to acquire Akademibokhandeln — which is, in my view, a typical acquisition for Volati. The book retailer is a well-run and profitable Group with strong cash flows and an extremely well-established market position. At the same time, Akademibokhandeln and Bokus are among the strongest consumer brands in Sweden with large customer bases. Akademibokhandeln has a growing customer club that currently comprises more than 1.3 million members. Together with the management, we will nurture these customer relations by continuing to develop the company’s offering through all channels,” says Mårten Andersson, Volati’s CEO. Volati has signed an agreement to acquire the shares in Akademibokhandeln Holding AB from Accent Equity 2012 (71.7%), J.P. Killberg Bokhandelsaktiebolag (11.1%), Stiftelsen Bokförlaget Natur & Kultur (11.1%) and Krasse & Co AB (1.0%). The management will remain as shareholders, with holdings amounting to around 5.2% of the shares in Akademibokhandeln Holding AB. The acquisition will take place at an estimated enterprise value (EV) of about SEK 760 million payable on completion and will be financed through Volati’s available cash funds and existing credit facilities. The purchase consideration for 100% of the shares amounts to SEK 263 million. The acquisition is being carried out at an EV/EBITDA multiple based of 6.1. Due to the acquisition, an expense of around SEK 10 million will be charged to Volati’s third-quarter earnings for transaction costs primarily pertaining to Volati’s financial advisor Keystone MCF.  Akademibokhandeln Holding AB has issued a SEK 500m secured bond, which was listed on Nasdaq Stockholm in May 2017. The bond extends for four years and carries an interest rate of STIBOR 3M + 6.0% and the outstanding bonds are redeemable by the company at 103% of face value from March 2019. As long as the bond loan is outstanding, restrictions exist governing how Volati can partake in cash flows from Akademibokhandeln’s operations. The acquisition is expected to have a positive impact on Volati’s earnings for 2017 and will contribute to increasing the return on equity. Akademibokhandeln is subject to significant seasonal variations with strong earnings in the fourth quarter of the year and weaker earnings in the first three quarters of the year. The company’s cash flows from operating activities amounted to SEK 94 million for 2016. Akademibokhandeln will comprise a new, fourth business area at Volati alongside Trading, Consumer and Industry. Volati’s strategy is to acquire operations at reasonable valuations with proven business models and leading market positions with stable cash flows that contribute to financing further acquisitions. Since January 2016, the Group has completed five acquisitions in addition to the ongoing acquisition of Akademibokhandeln. On completion of the acquisition of Akademibokhandeln, Volati’s leverage measured as its net debt to EBITDA ratio will be 1.0, which is well inside the company’s target of a maximum ratio of 3.0. This means Volati is able to make further acquisitions of new business units and complementary business operations. “Over the last few years, Akademibokhandeln has undergone major operational changes and has deservedly developed to capture the possibilities that transitional changes in the sector entail. Today, the company has well-trimmed operations that, with Volati’s support, can continue to be developed for the long term. In the current acquisition market, we consider the valuation reasonable for the company given its market position and financial profile,” continues Mårten Andersson. “We have built a business that now has an extremely strong offering in all the channels through which our customers want to purchase books and stationery. We look forward to being part of the Volati Group and having Volati as a long-term owner that I believe can contribute key know-how and support in developing operations moving forward,” comments Maria Hamrefors, Akademibokhandeln’s CEO. “In our time as owner, the management has strengthened Akademibokhandeln’s offering, position and profitability in a highly professional manner. We view Volati as a competent market participant that will be a good, long-term owner for the company,” says Martin Tisell, Chairman at Akademi­bokhandeln and Partner at Accent Equity Partners AB, investment advisors to Accent Equity 2012. Completion is planned for July 2017. The change of ownership will not mean any changes for the around 500 employees or the franchise holders who operate 28 of the stores. The acquisition is conditional on approval from the Swedish Competition Authority.  _______________________________________________________________________ Media and investor conference call 17 May at 10.00 a.m. Volati invites the media and investors to attend a presentation by conference call on Wednesday 17 May 2017 at 10:00 a.m. (CET). Volati’s CEO Mårten Andersson will present the acquisition and answer questions. The presentation will be held in Swedish.  · Call in on +46 8 5664 2664. Please notify of your participation and ring in good time.   · The audio webcast link can be found here .  Media and investor meeting at the Akademibokhandeln store, Mäster Samuelsgatan 28, 23 May at 09.00 a.m. Welcome to meet Akademibokhandeln’s CEO Maria Hamrefors and Volati’s CEO Mårten Andersson who will present the acquisition and Akademibokhandeln’s operations, and answer questions. _______________________________________________________________________ For further information, please contact: Mårten Andersson, CEO of Volati AB, +46 (0)72-735 42 84, marten.andersson@volati.se Mattias Björk, CFO Volati AB, +46 (0)70-610 80 89, mattias.bjork@volati.se  Volati AB (publ), Engelbrektsplan 1, SE-114 34 Stockholm, Sweden Tel: +46 (0)8-21 68 40, e-mail: info@volati.se, Corp. Reg. No. 556555-4317

WntResearch provides update on the preparations for the start of a Phase 2 study with the drug candidate Foxy-5

Patients treated so far with Foxy-5 have received an experimental drug formulation that complicates the logistics and is unsuitable for larger studies. WntResearch has therefore devoted considerable resources and time to securing a more effective pharmaceutical form ahead of the start of Phase 2, an effort that has now been successfully completed. "The availability of a more suitable drug formulation will mean a lot for the continued clinical development of Foxy-5 and is expected to increase the attractiveness of the project for potential future commercial partners," says Henrik Lawaetz, CEO, WntResearch AB. In an ongoing retrospective study, disease progression and tissue samples from patients with colon or rectal cancer are studied. The study aims at determining whether it would be suitable to extend the scope of the upcoming Phase 2 study to include patients with rectal cancer. The retrospective study has not been completed, but preliminary results indicate that Foxy-5 can be a valuable treatment for both colon and rectal cancer. In addition, the study result will serve as an important basis for determining the exact number of patients who need to be included in the Phase 2 study to reveal the treatment effect. "It is gratifying that the preliminary results from the retrospective study point to the possibility of including patients with rectal cancer, in addition to patients with colon cancer, in the phase 2 study," says Henrik Lawaetz, CEO, WntResearch AB. Foxy-5 is developed to reduce tumor spread. In a Phase 1b trial, the drug candidate has demonstrated a favorable safety profile, and has given clear signs of biological response. The Phase 1b results provide an important basis for selecting the dose in the Phase 2 trial, that is expected to start later this year. For further information contact: Henrik Lawaetz, CEOE-mail: hl@wntresearch.comTelephone: +46 72 702 4694 This information is information that WntResearch AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above May 17, 2017. About WntResearch WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread in the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastases. The need for a specific treatment to counteract metastasis is therefore in high demand. WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastases. The results from a completed phase 1 study show a favourable safety and pharmacokinetic profile, as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer of the colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden. For further information: www.wntresearch.com

Volvo pioneers autonomous, self-driving refuse truck in the urban environment

“There is amazing potential to transform the swift pace of technical developments in automation into practical benefits for customers and, more broadly, society in general. Our self-driving refuse truck is leading the way in this field globally, and one of several exciting autonomous innovations we are working with right now,” says Lars Stenqvist, Chief Technology Officer, Volvo Group. Volvo Group’s autonomous refuse truck is designed to make the driving safer in built-up areas, not least when reversing. Sensors continuously monitor the vehicle’s vicinity and the truck stops immediately if an obstacle suddenly appears in its path. The route is pre-programmed and the truck drives itself from one wheelie-bin to the next. The driver, who walks ahead of the reversing vehicle, can focus on refuse collection and does not have to climb into and out of the cab every time the truck moves to a new bin. “One important benefit of the new technology is a reduction in the risk of occupational injuries, such as wear in knee joints – otherwise a common ailment among staff working with refuse collection,” explains Lars Stenqvist. The autonomous truck also offers major environmental upsides. Gearchanging, steering and speed are constantly optimised for low fuel consumption and emissions. The joint project with Renova will continue until end of 2017. The autonomous truck currently being tested is fitted with a sensor system for identification, navigation, and monitoring of the vehicle’s vicinity. Most of this technology is also used in the autonomous truck for mining operations that Volvo Group unveiled in 2016. That self-driving truck is undergoing tests in the Kristineberg Mine in northern Sweden. Link to film: https://www.youtube.com/watch?v=zJSHXr8i-ZULink to high-resolution images: http://images.volvogroup.com/ More information about Volvo Group’s work with autonomous vehicles can be found at www.volvogroup.com/automation. For more information please contact Volvo Group’s press department, Henry Sténson +46 31 323 72 29 May 17, 2017 For more stories from the Volvo Group, please visit www.volvogroup.com/press. The Volvo Group is one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Group also provides complete solutions for financing and service. The Volvo Group, which employs about 95,000 people, has production facilities in 18 countries and sells its products in more than 190 markets. In 2016 the Volvo Group’s sales amounted to about SEK 302 billion (EUR 31,9 billion). The Volvo Group is a publicly-held company headquartered in Göteborg, Sweden. Volvo shares are listed on Nasdaq Stockholm. For more information, please visit www.volvogroup.com. 

Nuevolution AB (publ) announces its results for the third quarter 2016/17

Stockholm, 17 May 2017. Nuevolution AB (publ) announces its report for the third quarter 2016/17. The report is available on the company’s home page (www.nuevolution.com). The following is taken from the quarterly report. Third quarter 2016/17 (January-March 2017) summary Financials · Third quarter: Net sales amounted to SEK 1.6 million (6.0). First nine months: SEK 114.4 million (18.2). · Third quarter: Operating costs were SEK 31.4 million (27.6). First nine months: SEK 96.0 million (93.4). · Third quarter: Operating result was SEK -29.8 million (-21.7). First nine months: SEK 18.3 million (-75.2). · Third quarter: Net result amounted to SEK -29.0 million (-20.9). First nine months: SEK 1.8 million (-70.3). · Third quarter: Diluted earnings per share (EPS-D) was SEK -0.66 (-0.49). First nine months: SEK 0.04 (-2.05). · Cash and cash equivalents amounted to SEK 200.9 million as per March 31, 2017 (215.6). Net cash amounted to SEK 196.2 million as per March 31, 2017 (210.8). R&D - Massive Expansion of the Drug Discovery Engine and Promising Pipeline Progress · On Jan. 23, 2017, Nobel Laureate Dr. Robert J. Lefkowitz at Duke University and Nuevolution published an article representing a major breakthrough in the application of Nuevolution’s technology against GPCRs, an important target class, involved in signalling across cell-membranes. · On Feb. 14, 2017, we announced completion of our 40 trillion-member collection of molecules. This is about 20 million times more molecules than is generally available to any Big Pharma in their conventional drug discovery process, and likely the world’s largest collection of molecules made by synthetic chemistry. · Progress in pipeline: The internal pipeline progressed significantly during the quarter, where the RORγt inhibitor program outside the Almirall collaboration demonstrated positive results in animal models of IBD (Inflammatory Bowel Diseases), the selective BET bromodomain program progressed positively with solidification of anti-inflammatory activity data and benign toxicity profile in vitro and in vivo, the RORγt agonist immuno-oncology program demonstrated strong efficacy in cell based assays and is in preparation for in vivo proof-of-concept studies, and compounds with improved properties were obtained in the GRP78 CRT/ICR (UK) collaborative program. Progress in partnerships · Almirall: The collaboration is progressing according to plan. · Amgen: Cell based in vitro proof-of-concept was obtained in two Amgen projects. · Janssen Biotech: Expansion of the Janssen Biotech collaboration, thereby triggering an additional technology access fee payment of 600,000 USD (SEK 5.45 million). The payment will be recognized in the fourth quarter 2016/17 and onwards as services are rendered to Janssen Biotech. Events occurred after March 31, 2017 · Oveun AB (dormant), subsidiary of Nuevolution A/S, was divested on 7 April 2017 for an insignificant amount, and had an insignificant effect on the income statement and financial position. · The technology access fee payment from Janssen, announced on 6 March 2017, was received on 26 April 2017. Message of the CEO “During third quarter 2016/17, we have seen significant progress with major technological achievements, positive progress in partnerships as well as progression of the internal pipeline. Several biological studies and chemistry optimization activities are on-going in multiple programs with the objective of reaching important conclusions from on-going research during 2017” said Alex Haahr Gouliaev, CEO. Conference call and webcast On Wednesday 17 May at 14:00 CET, the company’s executive management will host a conference call and webcast presentation of the results and provide an update on partnering activities and pipeline programs. Access to the event can be obtained as follows: LIVE access on Wednesday 17 May at 14:00 CET Telephone numbers: SE: +46 85 664 2692 DK: +45 3544 5575 UK: +44 20 3008 9802 US: +1 855 831 5948 Webcast available at www.nuevolution.com in the Investors section and at www.financialhearings.com.  REPLAY access Webcast replay will be available on Nuevolution’s website at www.nuevolution.com in the Investors section and at www.financialhearings.com.  For more information, please contact: Alex Haahr Gouliaev, CEO Phone: +45 3913 0902 Email: ahg@nuevolution.com  Henrik Damkjær Simonsen, CFO Phone: +45 3913 0947 Email: hs@nuevolution.com  Information about Nuevolution AB (publ) Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology. This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was sent for publication, through the agency of the contact persons set out above, on Wednesday 17 May 2017, 8:30 (CET). Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com.

Itiviti wins industry award for “Most Innovative New Product”

Itiviti Analyst, with its pioneering suite of five modules, helps eliminate the mandatory direct effects of MiFID II. Itiviti Analyst manages the most demanding regulatory issues, enabling firms to focus on business innovation and growth. “Itiviti Analyst impressed our judges because it offers an original and effective solution to help financial firms handle their MiFID II regulatory and compliance issues,” said Matthew Clements, Editor of The Technical Analyst. “MiFID II will have a significant impact on the European trading landscape, and Itiviti Analyst stands out by not only addressing compliance, but also supporting firms’ efforts to capitalize on business opportunities which may arise as updated regulation is expected to reshape the trading landscape.” Established in 2004, The Technical Analyst brings institutional technical research and strategy ideas to the global financial markets, supported by regular events and training courses. With a readership comprising traders, fund managers and hedge funds, the Technical Analyst reports on and publishes technical analysis, market outlooks and trading strategies from banks, brokers and academics. ”We are very proud to accept the Technical Analyst Award for Itiviti Analyst,” said Jonas Hansbo, Chief Strategy Officer, Itiviti. “The introduction of Itiviti Analyst is indicative of our long-standing commitment to game-changing innovation. This strategic approach to development has never been more fitting than today, as firms are preparing for a new market structure shaped by major regulatory change.” Itiviti Analyst is a vendor-agnostic solution designed to address the entire scope of MiFID II. It is implemented with minimal impact on existing trading infrastructure while covering all asset classes (equities, ETFs, derivatives and bonds). The following functional modules are currently offered: MAR (Market Abuse Regulation), Algo Monitoring, Best Execution, Market Maker Compliance, and TCA (Transaction Cost Analysis). About ItivitiItiviti is a world-leading technology provider for the capital markets industry. Trading firms, banks, brokers and institutional clients rely on Itiviti technology, solutions and expertise for streamlining their daily operations, while gaining sustainable competitive edge in global markets. With 13 offices and serving more than 400 customers worldwide, Itiviti was formed by uniting Orc Group, a leader in trading and electronic execution, and CameronTec Group, the global standard in financial messaging infrastructure and connectivity. From its foundation in 2016, Itiviti has a staff of 400 and an estimated annual revenue of SEK 700 million. Itiviti is committed to continuous innovation to deliver trading infrastructure built for today’s dynamic markets, offering highly adaptable platforms and solutions, enabling clients to stay ahead of competitive and regulatory challenges. Itiviti is owned by Nordic Capital Fund VII. For further information, please contact:Jonas Hansbo, Chief Strategy Officer, Itiviti, Tel. +46 70 652 51 93Christine Blinke, Chief Marketing Officer, Itiviti, Tel. +46 739 01 02 01

Sandvik Materials Technology intends to divest the welding and stainless wire businesses

In order to further consolidate the product portfolio and improve its long term performance, Sandvik Materials Technology intends to divest parts of its wire operations. · To be divested: welding and stainless wire. These businesses are subject to intense competition and Sandvik Materials Technology does not hold a No. 1-2 market position. In 2016 the wire businesses, which are to be divested, generated total annual revenues of about 700 million SEK. · To remain in Sandvik Materials Technology: Kanthal wire for industrial heating etc. These businesses will be included in the Kanthal product area and are regarded as core businesses due to the strong market positions and growth potential. In 2016 operations now transferred into the Kanthal product area had annual revenues of about 800 million SEK. A charge of -450 million SEK related to the transaction will impact the result for the second quarter 2017. This is primarily impairments related to fixed assets. The cash flow impact from the transaction is expected to be positive. "The divestment of the welding and stainless wire businesses will make Sandvik Materials Technology more focused on its core operations; advanced stainless steels and special alloys for the most demanding industries. We will continue to develop our core businesses to ensure long term value creation. A new organizational structure is being created, effective as from 1 July 2017, whereby each product area will be responsible and accountable for the entire value chain and its results. The four new product areas will be Tube, Kanthal, Powder and Strip", says Petra Einarsson, President of business area Sandvik Materials Technology. For further information, contact Ann-Sofie Nordh, Vice President Investor Relations, tel: +46 8 456 14 94 or Carina Aspenberg, Media and PR Manager, tel: +46 70 616 01 19. Stockholm, 17 May 2017 Sandvik AB 

Kindred’s Maris Bonello wins Innovator of the Year 2017

Kindred Group’s (previously Unibet Group) Integrity Analytics Manager, Maris Bonello, won the prestigious award “Innovator of the Year” at the yearly Women in Gaming Award show on Friday 12 May at the Savoy hotel in London. Maris was nominated for her efforts in developing the award-winning system Player Safety Early Detection System (PS-EDS). The detection system alerts responsible gaming experts at Kindred when customers might be developing a problem, which is then processed/interpreted on a case-by-case basis by Kindred’s trained professionals in responsible gaming and player safety. The proprietary technology combined with expert human discretion and judgment has proven to be a highly effective tool to protect our customers and our business from unhealthy and unsustainable gambling practices “I am delighted to see Maris yet again be awarded for her dedicated and hard work in ensuring that our customers enjoy gambling in a healthy and sustainable way. It has always been, and will always be, a key priority for Kindred to offer our customers a fun, safe and entertaining experience. The work Maris and her team conduct is critical in achieving this”, says Daniel Gambin, Head of Player Safety at Kindred Group. Kindred Group invests heavily in responsible gaming and sees this as a fundamental pillar in building long-term customer relationships. Helping players stay in control of their gambling, providing a safe and secure online environment and preventing fraud, all contribute to the Group’s aim of providing the best customer experience.

Orfadin® capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the Saudi Food and Drug Administration (SFDA) has approved Orfadin® (nitisinone) capsules in all strengths (2 mg, 5 mg, 10 mg and 20 mg) for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. HT-1 is a progressive, rare genetic disease that may result in liver and kidney complications and in most cases fatal if untreated. In the most common form of the disease, symptoms arise within the first six months of the child's life. “We are very pleased that Orfadin has received approval from the SFDA. The Kingdom of Saudi Arabia is the largest market in the Middle East, and our focus will now be to ensure timely and sustainable access to treatment for people living with HT-1 on this market”, says Ahmad Abu-Dahab, Regional Director Middle East & Turkey. “Sobi’s vision is to support that patients are diagnosed at birth, receive effective and sustainable therapy, and go on to live full and healthy lives no matter where in the world they live. This approval is another important step on this journey,” says Bodil Jonason, Vice President Commercial Operations and Head of Global Brands at Sobi. --- About Orfadin®People with hereditary tyrosinemia type 1 (HT-1) have problems breaking down an amino acid called tyrosine. Toxic by-products are formed and accumulate in the body, which can cause liver, renal and neurological complications. Approximately 1,000 persons worldwide are identified as living with HT-1 today. Orfadin® (nitisinone) blocks the breakdown of tyrosine, thereby reducing the amount of toxic tyrosine by-products in the body. Patients must maintain a special diet in combination with Orfadin treatment as tyrosine is not adequately broken down. Orfadin is a proprietary product and is developed by and made available globally by Sobi. Before Orfadin became available, the survival rate in HT-1 was 29 per cent after two years for children who developed symptoms before two months of age. [1]  After the introduction of Orfadin, the survival rate is 93 per cent after two years in patients with treatment initiation before two months of age.[2]  For full European prescribing information, please visit the EMA website.  For full US prescribing information please see www.orfadin.com  About Sobi™ Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more informationplease contact Media relations      Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor RelationsT: + 46 708 73 40 95, + T: +1 347 224 0819,46 8 697 31 74   +1 212 579 0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  ---------------------------------------------------------------------- [1]  van Spronsen FJ, Thomasse Y, Smit GP, et al. Hepatology. 1994;20(5):1187-1191 [2]  Orfadin EPAR: Product information 26/01/2017 

Lippulaiva to house the world’s largest geothermal power plant in a shopping centre

Citycon is building the new state-of-the-art Lippulaiva shopping centre in Espoo, Helsinki Area. The heating and cooling of the shopping centre will be produced by renewable, carbon-neutral geothermal energy derived from the bedrock. Lippulaiva will use all of the heating and cooling energy provided by the plant, so the energy production will be local. The plant will make Lippulaiva almost completely self-sufficient in terms of heating and cooling energy. Citycon is partnering in the project with energy company Adven, who will make the investment in the geothermal plant and will be in charge of contracting as well as operation during use of the facility. Lippulaiva’s plant is as far as known the largest geothermal heating and cooling facility in the world to be constructed in connection with a retail property.The total output of the facility is roughly 4000kW, equalling 500 residential house heat pump systems. The shopping centre’s gross leasable area is 42,000 square metres, while the geothermal power plant will provide heating and cooling for of a gross area of 57,000 square metres in total. In addition to the leasable premises, the system provides heating and cooling for the parking garage and to the service floors located in connection to the shopping centre. Self-sufficiency and environmental awareness  A shopping centre requires extensive cooling. In addition to the warm summer months, cooling is needed e.g. for the grocery stores’ refrigeration equipment throughout the year. Previously, Lippulaiva’s cooling was produced by blowing the cooled condensation heat into the air, but in the new facility, condensation heat will be recovered and recycled by storing it in the bedrock. “With geothermal energy, cooling is produced locally and in an environmentally friendly manner. We no longer need to place condensers on the roof of the shopping centre; instead, the roof can be used for landscaping, or it can house solar panels or be a setting for recreational use. The third important aspect is the continuously increasing price of energy. The geothermal power plant will make us more self-sufficient and our energy costs more predictable,” says Citycon’s Project Director Heikki Alén. A total of 170 geothermal wells will be drilled into the bedrock underneath Lippulaiva. Each of the wells will be approximately 300–350 metres deep, making the total length of the wells in the system 50 kilometres. “Cooling is obtained from the bedrock in the summer and heat is transferred into it in exchange. The bedrock operates like a battery: the heat stored in it during the summer can be used during the heating season”, says Timo Koljonen, VP, Geoenergy, at Adven Group, as he describes the operating principle of the power station. Drilling the geothermal wells began at the beginning of May 2017 and will continue until 2018. The work is scheduled to coincide with the construction of the new Lippulaiva shopping centre “According to its values, Espoo is a responsible forerunner. We are committed to developing Espoo in a socially, ecologically and financially sustainable manner. According to an international comparison study, Espoo is the most sustainable city in Europe and we wish to maintain this status in the future as well. Citycon’s geothermal heating plant is an excellent example of how Espoo is implementing its strategy of being a pioneer in combatting climate change,” says Olli Isotalo, Head of Technical and Environment Services for the City of Espoo.    “There are great opportunities in the real estate sector to reduce energy consumption while also reducing energy-related environmental impacts and maintenance costs. Energy efficiency is a crucial factor in the strategy of Citycon. Reducing energy consumption, improving energy efficiency as well as using and producing renewable energy are all part of our strategy. This includes carrying out feasibility studies on renewable energy in connection with our development projects, and the geothermal energy solution at Lippulaiva is a good example of this”, says Wilhelm Ehrnrooth, Sustainability Analyst at Citycon. Adven has earlier delivered a geothermal power station for Citycon in the Jakobsbergs Centrum shopping centre in Sweden. Helsinki, 17 May 2017CITYCON OYJAdditional information: Heikki Alén, Project DirectorTel. +358 (0)40 567 6619heikki.alen@citycon.com Timo Koljonen,VP Geoenergy Finland, AdvenTel. +358 50 466 6999timo.koljonen@adven.com Citycon Oyj (Nasdaq Helsinki: CTY1S) is a leading owner, developer and manager of urban grocery-anchored shopping centres in the Nordic and Baltic regions, managing assets that total EUR 5 billion and with market capitalisation of EUR 2 billion. For more information about Citycon, please visit www.citycon.com Adven is the leading industrial and commercial outsourced energy and water infrastructure and services provider in Finland, Sweden and Estonia. Adven holds long-term contracts to build, own and operate plants producing process steam, heat and cold at its clients' production facilities. In addition to the tailored energy solutions, Adven provides district heating, space heating and cooling through geothermal solutions and has a gas distribution/resale business. Adven delivers energy at around 140 industrial sites, operates around 50 district heating sites and networks, and 15 geothermal sites corresponding to an installed capacity of approximately 1,500MW. www.adven.com

NOTICE OF ANNUAL GENERAL MEETING IN ARCAM

Shareholders who wishes to participate in the meeting shall: -      be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB as of June 10, 2017; and -      give notice of their attendance to the company no later than June 12, 2017, 12.00 p.m. CET at the address:        Arcam AB, Att: Hendrik Kangasmuukko, Box 11920, SE-404 39, Göteborg, Sweden or via e-mail to legal@arcam.com. In the notice of attendance, the shareholder shall specify its name, personal or company identification number, address, telephone number and, if applicable, the number of assistants the shareholder wishes to bring (maximum of two). Shareholders represented by proxy shall present a written power of attorney which as at the day of the Annual General Meeting may not be older than five years. Proxies and representatives of legal persons shall submit authority documents prior to the Annual General Meeting (signed and dated power of attorney and/or current certificate of registration). Power of attorney forms are available via www.arcamgroup.com. Power of attorney forms may also be obtained from the company or ordered by e-mail at the e-mail address indicated above. Shareholders whose shares are registered in the name of a nominee must temporarily re-register the shares in their own name in order to be entitled to participate in the Annual General Meeting. Such re-registration shall be made with Euroclear Sweden AB at the latest on June 10, 2017 and the nominee shall therefore be notified thereof in due time before the stated date. 1.       Opening of the meeting 2.       Election of chairman of the meeting 3.      Preparation and verification of the voting list 4.      Election of one or two persons to verify the minutes 5.      Determination of whether the meeting has been duly convened 6.      Approval of the agenda 7.      Presentation of the annual report and the auditors’ report as well as the consolidated accounts and auditors’ report on the consolidated accounts 8.      Resolution on (a) adoption of the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet, (b) allocation of the company’s result as shown in the adopted balance sheet and (c) discharge from liability of the directors and the managing director           The proposed resolution by a minority shareholder on distribution of profit according to Chapter 18, Section 11, of the Swedish Companies Act (Sw. aktiebolagslagen) will be handled in connection with item 8(b) 9.      Determination of the number of directors 10.    Determination of the remuneration to the Board of Directors and the auditor 11.    Election of directors and chairman 12.    Election of auditor 13.    Resolution on guidelines for remuneration to senior management   14.    Resolution on authorization to the Board of Directors to resolve on rights issues   15.    Resolutions on minority shareholder proposals in relation to (a) engagement of an independent financial advisor and (b) establishment of an independent clearance committee 16.    Closing of the meeting Item 2 – Election of chairman of the meeting   The Board of Directors proposes that attorney Martin Wedén of Wistrand law firm is elected chairman of the meeting. Item 8(b) – Allocation of the company’s result as shown in the adopted balance sheet The Board of Directors proposes that the Annual General Meeting resolves that the funds at the disposal of the Annual General Meeting shall be carried forward and consequently that there shall be no distribution of profit. The Board of Directors have received a proposal from the shareholders Elliot International L.P. and The Liverpool Limited Partnership, that it is resolved to distribute profits in accordance with Chapter 18, Section 11, of the Swedish Companies Act. Item 9 – Determination of the number of directors   The shareholder GE Sweden Holdings AB (a company controlled by General Electric Company) proposes that the Annual General Meeting resolves that the Board of Directors shall consist of five (5) directors and no deputy director, for the period until the end of the next Annual General Meeting. Item 10 – Determination of the remuneration to the Board of Directors and the auditor  The shareholder GE Sweden Holdings AB proposes that the Annual General Meeting resolves according to the following: Directors who are employed by companies in the General Electric Company group shall not be entitled to any remuneration by the company. For the period up until the end of the next Annual General Meeting, the remuneration to the chairman of the Board of Directors shall amount to SEK 750,000 and the remuneration to each other director shall amount to SEK 450,000. Further, SEK 25,000 shall be paid to each director per year for committee work. Provided that tax conditions so permits, it is cost neutral for the company and a written agreement between the company and a limited liability company which is wholly-owned by a director is entered into, the company may approve that the board fee is invoiced by such director’s wholly-owned company (in such case, the invoiced fee shall be increased with an amount corresponding to social security payments and value added tax pursuant to law). The Board of Directors proposes that remuneration to the auditor shall be paid against approved invoices. Item 11 – Election of directors and chairman  The shareholder GE Sweden Holdings AB proposes that the Annual General Meeting resolves to re-elect Göran Malm, Lars Bergström, Carlos Härtel, Riccardo Procacci and Vandana Sriram as directors of the Board of Directors for the period up until the end of the next Annual General Meeting and that Göran Malm is re-elected as the chairman of the Board of Directors. Item 12 – Election of auditor The Board of Directors proposes that the Annual General Meeting resolves that the company shall have one auditor without any deputy auditor and that Ernst & Young shall be re-elected as auditor for the period up until the end of the next Annual General Meeting (authorized public accountant Stefan Kylebäck is intended to serve as auditor-in-charge). Item 13 – Resolution on guidelines for remuneration to senior management The Board of Directors have proposed the guidelines for remuneration to senior management made available on the company’s webpage www.arcamgroup.com. Item 14 – Resolution on authorization to the Board of Directors to resolve on rights issues The Board of Directors proposes that the Annual General Meeting resolves to authorize the Board of Directors to, on one or more occasions before the next Annual General Meeting, resolve on issues of shares with pre-emption rights for the company’s shareholders (rights issues). The aggregate increase in the share capital under the authorization shall not exceed SEK 5,000,000.  As a result of the company's business plan, including growth, and current cash position, the Board of Directors expects that the company will need external capital during the coming year. This authorization provides the Board of Directors with the flexibility required to complete an external equity capital raise.  The Board of Directors further proposes that the Annual General Meeting resolves to authorize the Board of Directors, or a person appointed by the Board of Directors, to make such minor adjustments to the resolution as may be required in connection with registration of the resolution with the Swedish Companies Registration Office or with Euroclear Sweden AB or due to other formal requirements. Item 15 – Resolutions on minority shareholder proposals in relation to (a) engagement of an independent financial advisor and (b) establishment of an independent clearance committee 15(a) Engagement of an independent financial advisor Shareholders Elliot International L.P. and The Liverpool Limited Partnership proposes that the Annual General Meeting resolves that ”an independent financial advisor is retained in order to review and document the corporate benefit of the company (and its subsidiaries) in relation to any contemplated or effective agreements, transactions, sales, resource transfers or collaborations (including but not limited to intellectual property and research), and any other co-operations with closely related parties of the company.” 15(b) Establishment of an independent clearance committee Shareholders Elliot International L.P. and The Liverpool Limited Partnership proposes that the Annual General Meeting resolves that ”an independent clearance committee is established in order to, on a case by case basis, handle issues relating to disclosure of information from the company (and its subsidiaries) to closely related parties and determine if such disclosure of information can be made in the best interest of the company and all its shareholders, and in order to review and approve, under the condition of satisfaction of corporate benefit on strict commercial terms and arm’s length terms without disadvantage to any shareholder, any contemplated agreements, transactions, sales, resource transfers or collaborations (including but not limited to intellectual property and research), and any other co-operation with closely related parties of the company.” Other information   The total number of shares and votes in the company is 20,746,585 at the time of this notice. 20,546,585 of the shares are ordinary shares and 200,000 are preferential shares, called C-shares, which are not submitted for trading at Nasdaq Stockholm. The company holds 152 ordinary shares and all 200,000 preferential shares, called C-shares in treasury. Relevant documents, including the shareholder GE Sweden Holdings AB’s complete proposals and the auditors statement according to Chapter 8, Section 54, of the Swedish Companies Act, will be available at the company’s address Arcam AB (publ), Krokslätts Fabriker 27A, 431 37 Mölndal, and at the company’s website, www.arcamgroup.com at the latest three weeks before the Annual General Meeting and will be sent to shareholders who request so and who inform the company of their postal address. Shareholders are reminded of their right to request information according to Chapter 7, Section 32, of the Swedish Companies Act. ____________________ Mölndal in May 2017 Arcam AB (publ)

Cinnober appoints Alastair Goodwin to CEO of its new surveillance venture

Cinnober  recently announced the acquisition of the business and assets of Ancoa Software, the UK-based market surveillance specialist company. This business forms a new subsidiary within the Cinnober group and Alastair Goodwin has now been appointed CEO for the entity, that will provide contextual surveillance and insightful analytics for exchanges, regulators, buy & sell-side firms. Goodwins’s most recent position was Head of Business Development at Boat Services Ltd, a UK based Cinnober subsidiary that provides technology services to the banking and insurance sectors. Notably, he drove the partnership between Boat and the London Stock Exchange to bring together their reporting services and form TRADEcho. TRADEcho provides fixed income and equity trade publication, with MFID II on the horizon the service is being expanded to support all MiFID II asset classes. Before Boat, he worked at Goldman Sachs within the Equities One Delta Strategy team as an Executive Director. His focus being on emerging markets, market structure, trading cost and quality optimisation. “Alastair has been crucial in how we during recent years have built and launched our market leading offering within trade reporting. He’s ideal to cultivate the significant potential we see in the Ancoa product and the talented development team behind it,” says Veronica Augustsson, CEO of Cinnober. “The surveillance service is a great addition to our product suite, complementing Cinnober’s traditional core market of exchanges as well as our newer initiatives with international banks and brokerages. I am confident that under Alastair’s leadership, Ancoa will be successfully integrated within the Cinnober group and that it will become a prosperous company, delivering a quality service.” The Ancoa offering is based on a highly sophisticated, yet easy to deploy and simple to use, monitoring and surveillance platform that helps firms take full control of their regulatory, reputational and operational risks across markets, functions and asset classes. The customers of today includes Convergex, MarketAxess, Linear Investments, Energie Steiermark and Cenkos Securities. Following the acquisition Cinnober has started a three months’ integration phase to maximize synergies and leverage cost efficiencies. Cinnober is a world-leading and independent supplier of financial technology to marketplaces and clearinghouses. The portfolio of offerings includes price discovery and matching, real-time risk management, clearing and settlement, index calculation, data distribution and surveillance. Customers include major exchanges with extreme demands on reliability and performance, such as the Australian Securities Exchange, B3 (formerly BM&FBOVESPA), Dubai Gold & Commodities Exchange, Euronext, Japan Exchange Group, Johannesburg Stock Exchange, the London Metal Exchange, LME Clear, NYSE and the Stock Exchange of Thailand. For further information or discussion, please contact:Fredrik BacklundHead of Corporate CommunicationsCinnober Financial TechnologyTel. +46-73 403 12 39fredrik.backlund@cinnober.com (fredrik.backlund@cinnober.com%20) About CinnoberCinnober provides solutions and services to leading trading and clearing venues, including exchanges, clearinghouses, banks and brokers. Cinnober’s solutions are largely based on the TRADExpress™ Platform, incorporating everything needed for mission-critical solutions in terms of performance, robustness and flexibility. The portfolio of offerings includes price discovery and matching, real-time risk management, clearing and settlement, index calculation, data distribution and surveillance. Cinnober’s customers include the Australian Securities Exchange, BM&FBOVESPA, Dubai Gold & Commodities Exchange, Euronext, Japan Exchange Group, Johannesburg Stock Exchange, the London Metal Exchange, LME Clear, NYSE and the Stock Exchange of Thailand. For additional information, please visit www.cinnober.com

Advenica appoints Markus Gursch as CEO in Austria

As part of the company’s progress in Europe, the Swedish IT-security company Advenica continues to invest in Austria by appointing Markus Gursch as CEO of Advenica Austria. Markus comes from Barracuda Networks, provider of network security and data protection, where he was Vice President Operations EMEA. Advenica's establishment of a subsidary in Austria follows the success of last year when winning a 10-year framework agreement with the Austrian Armed Forces and a related order regarding the company's encryption solutions. "We see great potential in the Austrian market for the company's products and, just as in Finland, we want to invest fully in deepening our existing relationships by being locally present. With Markus' cybersecurity expertise and customer focus, we are able to expand our customer segment and our offer further in the Austrian market", says Einar Lindquist, CEO, Advenica AB. Markus Gursch was part of establishing and build-up the IT security company Phion AG, later aquired by Barracuda in 2010. Markus have had several leading positions at phion/Barracuda and was an authorized officer for years too. Since 2013 he was Vice President Operations for EMEA. He has experience in Technical Support for Security Products, Post Sales Support, Sales Backoffice, EMEA IT, Sales and customer training (technical and product trainings), Software development in the web area, Datacenter development in EMEA. Markus Gursch will assume the new position as CEO for Advenica in Austria July 1, 2017. "Advenica is a well-known IT security provider at the highest level and I look forward to becoming a part of the company. With my knowledge of the cybersecurity market and customers, I see great potential for Advenica's solutions and to grow the business in the Austrian market", says Markus Gursch, CEO, Advenica Austria. For further information, please contact: Einar Lindquist, CEO Advenica AB, +46 (0)704 29 98 39, einar.lindquist@advenica.com This information is information that Advenica AB is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.10 a.m. CET on May 17th, 2017.

Interim Report January-March 2017

January – March 2017 · Net sales decreased with 4 percent to SEK 545 million (567) · Operating profit before depreciation increased to SEK 30 million (24) · Operating profit increased to SEK 19 million (11) · Non-recurring items amounted to SEK 0 million (430) · Earnings after tax amounted to SEK 4 million (343) · Earnings per share amounted to SEK 0.01 (1.75) · Cash flow after investing activities amounted to SEK 22 million (7) Bong is one of the leading providers of specialty packaging and envelope products in Europe and offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.1 billion and about 1,500 employees in 15 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its shares are listed on Nasdaq Stockholm (Small Cap). For further information, please contact Håkan Gunnarsson, CFO for Bong AB.  Tel (switchboard) 46 44-20 70 00       This information is information that Bong AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.30pm CET on May 17 2017.   

SCA’s Extraordinary General Meeting

The Extraordinary General Meeting decided that the number of Board members in SCA (the future forest products company) would amount to nine with no deputies. Charlotte Bengtsson, Lennart Evrell, Ulf Larsson, Martin Lindqvist and Lotta Lyrå were elected as new Board members. The newly elected members will join the Board of the future forest products company SCA on the first day of trading in the shares of Essity Aktiebolag (publ) on Nasdaq Stockholm. Accordingly, the Board of Directors of SCA will, as of the above date, consist of Pär Boman (Chairman), Charlotte Bengtsson, Lennart Evrell, Annemarie Gardshol, Ulf Larsson, Martin Lindqvist, Lotta Lyrå, Barbara Milian Thoralfsson and Bert Nordberg. Board members Ewa Björling, Maija-Liisa Friman, Magnus Groth, Johan Malmquist, Lars Rebien Sörensen and Louise Svanberg have declared that they are not available for election to the Board of the future forest products company SCA, following the listing of Essity Aktiebolag (publ) (formerly with the corporate name of SCA Hygiene AB). However, following the listing, they will remain as members of the Board of the hygiene and health company Essity Aktiebolag (publ). The Board of Directors of Essity Aktiebolag (publ) consist of Pär Boman (Chairman), Ewa Björling, Maija-Liisa Friman, Annemarie Gardshol, Magnus Groth, Johan Malmquist, Barbara Milian Thoralfsson, Bert Nordberg, Lars Rebien Sörensen and Louise Svanberg. The above resolutions concerning the number of Board members and the election of new Board members are conditional upon the shares in Essity Aktiebolag (publ) being admitted to trading on Nasdaq Stockholm. In the event the condition is not fulfilled, there will be no change to the Board elected at the Annual General Meeting on April 5, 2017. The minutes of the Extraordinary General Meeting will be published on the company’s website, www.sca.com, within two weeks.

Tobii acquires Sticky, a leading solution provider for market research studies based on webcam eye tracking

Tobii today announced that it has acquired substantially all of the assets of Sticky, a company that provides a cloud-based product enabling large-scale market research studies using webcam eye tracking. Sticky will be integrated with the business unit Tobii Pro, the global leader in eye-tracking research solutions. “I am very pleased to welcome Sticky into the Tobii family. The acquisition of Sticky delivers on our strategy to grow our efforts within large-scale eye tracking data analytics and expands Tobii Pro’s market research offering”, said Henrik Eskilsson, CEO of Tobii. “Tobii Pro leads the market in bringing eye-tracking insights to commercial brands, researchers and organizations and Sticky’s cloud-based platform will be a great complement to our existing eye-tracking solutions”, said Tom Englund, president of Tobii Pro. Sticky was established in 2009. It is headquartered in San Francisco with offices in New York and Stockholm and employs 15 people. Sales for 2016 were approximately USD 1.5 million (approximately SEK 13 million) with an EBIT of USD -2.8 million (approximately SEK -25 million). The acquisition will be paid with cash at hand, with an option to provide part of the consideration in Tobii shares. Prior to the transaction, Tobii was a minority shareholder in Sticky. This information is information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on May 17, 2017, at 14:05 p.m. CET.

Agromino: Major Shareholder Announcement

Agromino A/S hereby pursuant to Section 29 of the Danish Securities Trading Act announces receipt of the following major shareholder’s notification: Mr. Petr Krogman on 17 May 2017 acquired through Mabon additional 16,276,176 shares in Agromino A/S and now indirectly via Mabon (Czech Identification Number: 28904681, registered in the Commercial Register maintained by the Municipal Court in Prague, section B, insert file No. 15302) holds 96,425,086 shares and voting rights in Agromino A/S, corresponding to 5.53% of the total share capital and of the total voting rights of Agromino A/S. Mr. Petr Krogman owns and controls Mabon that is the direct owner of the shares.  Investor enquiries  Mr. Simon Boughton, CEO of Agromino A/S   Tel: +372 6191 500, e-mail:  mail@agromino.com  About Agromino  Agromino is an integrated soft commodities production, storage and trading company with operations in Ukraine, Russia and Estonia. Agromino shares are traded on the main market of Nasdaq Stockholm. For subscription to Agromino A/S announcements please contact us: mail@agromino.com If you do not want to receive Agromino A/S press releases automatically in the future please send an e-mail to the following address: unsubscribe@agromino.com. This information is information that Agromino A/S is obliged to make public pursuant to the Danish Securities Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 14:30 CET on 17 May 2017.

Accent Equity divests Akademibokhandeln to Volati

Akademibokhandeln is the market leading book retailer in Sweden with a market share of about 35% of consumer book retailing and has a strong offering for all product and delivery formats. With 108 stores nationwide, 80 under its own management and 28 run as franchises, together with online sales under the Akademibokhandeln and Bokus brands, the company operates modern and profitable sales channels focused on consumers, companies and public sector operations. Akademibokhandeln has a growing customer club that currently comprises more than 1.3 million members. For 2016, the Akademibokhandeln Group’s net sales amounted to SEK 1.8 billion and EBITDA to SEK 125 million. “In our time as owner, the management has strengthened Akademibokhandeln’s offering, position and profitability in a highly professional manner,” says Martin Tisell, Chairman at Akademi­bokhandeln and Partner at Accent Equity Partners AB, investment advisor to Accent Equity 2012. “We view Volati as a competent industrial group that will be a good, long-term owner for the company.” “We have built a business that now has an extremely strong offering in all the channels through which our customers want to purchase books and related products,” comments Maria Hamrefors, Akademibok­handeln’s CEO. “We look forward to being part of the Volati Group and having Volati as a long-term owner that I believe can contribute know-how and support in developing operations moving forward.” Volati was founded in 2003, and today comprises some 40 operating companies divided into 12 business units organized in three business areas: Trading, Consumer and Industry. Volati has operations in 16 countries, with a total of around 1,200 employees and annual sales of approximately SEK 3 billion. “We are extremely pleased and proud to be able to acquire Akademibokhandeln,” says Mårten Andersson, Volati’s CEO. “The book retailer is a well-run and profitable group with strong cash flows and an extremely well-established market position. Together with management, we will nurture these customer relations by continuing to develop the company’s offering through all channels.” Completion is planned for July 2017. The change of ownership will not mean any changes for the around 500 employees or the franchisees who operate 28 of the stores. The acquisition is conditional on approval from the Swedish Competition Authority. For further information, please contact:Martin Tisell, Chairman of Akademibokhandeln Holding AB (publ), +46 70 877 65 20, martin.tisell@accentequity.se.Maria Hamrefors, CEO Akademibokhandeln Holding AB (publ), +46 70-601 92 05, maria.hamrefors@akademibokhandeln.se Mårten Andersson, CEO of Volati AB, +46 72-735 42 84, marten.andersson@volati.se 

SciBase increases its commercial focus with three new Board members

At the SciBase Annual General Meeting held yesterday, three new members were elected to the Board of Directors. Dr. Thomas Taapken, Diana Ferro and Thomas Eklund are the new members of the Board while Tord Lendau (Chairman), Per Aniansson and Renee Aguiar-Lucander were re-elected. Common to the three newly elected is their commercial focus and experience from the medtech industry. Thomas Taapken, Diana Ferro and Thomas Eklund will also contribute with insights into the international market and the first two also have extensive knowledge and experience of the German market.    - As our focus on sales and marketing is becoming clearer, it’s natural that this is reflected on the board as well. Thomas Eklund has been active in several companies in our situation. Thomas Taapken and Diana Ferro have a very good knowledge of the German market and their international experience will be useful going forward. Germany continues to be our growth engine and we also look forward to receiving a decision from the FDA regarding the US market around mid-year, says Tord Lendau, chairman of the board, SciBase. Dr. Thomas Taapken is today CFO at Medigene AG, a listed biotech company focused on immunotherapy for different types of leukemia. He has a commercial focus and has significant market experience, especially from the German market. In Germany he has worked with reimbursement but he has also been part of a successful PMA process with the FDA. Dr. Thomas Taapken is based in Germany.  Diana Ferro is the CEO of MedSkin Solution AG, which develops products within medical care, aesthetic care and professional skin care. Diana Ferro has experience in leading global organizations and has driven sales and marketing efforts through distribution networks in several markets. Diana Ferro is also based in Germany.   Thomas Eklund is an independent advisor, investor and Board member within the Health Care industry. Thomas has extensive experience from senior positions within the financial sector such as CEO & Head of Investor Growth Capital, where he was responsible for the life science investments, and also within Handelsbanken. -I would also like to take the opportunity to thank the three resigning members of the board, Stig Ollmar, Carsten Browall and Andreas Pennervall, for all their hard work and great commitment to SciBase, says Tord Lendau, Chairman of the Board, SciBase. For further information please visit www.scibase.com or contact: Simon Grant, CEOTel: +46 72 887 43 99E-mail: simon.grant@scibase.com  About Skin CancerSkin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly. About SciBase and Nevisense SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.  

Bulletin from The Annual Shareholders’ Meeting in Polygiene AB (Publ) on May 17, 2017

Resolution on adoption of accounts and distribution of the company’s profit The annual shareholders’ meeting resolved to adopt the profit and loss statement and balance sheet. The annual shareholders’ meeting also resolved to distribute the company’s profit in accordance with the proposal from the board in the annual report meaning that no dividends are paid for the financial year 2016 and that available funds are carried forward to a new account. Discharge from liability for board members and the CEO The annual shareholders’ meeting resolved to discharge the board of directors and the CEO from liability for the financial year 2016.  Election of board members and auditor as well as remuneration for the board members and auditor The annual shareholders’ meeting resolved, in accordance with the proposal from the Nomination Committee, to re-elect Lennart Holm, Mats Georgson, Richard Tooby, Jonas Wollin and Jonas Sjögren as ordinary board members and to elect Daniel Oelker as new ordinary board member. Richard Tooby was elected as new Chairman of the board. Remuneration to the board shall be paid with SEK 225,000 to the Chairman of the board and with SEK 125,000 to each of the other board members. Furthermore, the annual shareholders’ meeting resolved, in accordance with the proposal from the Nomination Committee, to re-elect Ernst & Young Aktiebolag as the auditor and that remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Resolution on instruction and charter for the Nomination Committee The annual shareholders’ meeting resolved, in accordance with the proposal from the Nomination Committee, that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise four members – one representative for each of the three largest shareholders on the last banking day in September, together with the Chairman of the board. Furthermore, an instruction and charter for the Nomination Committee was adopted. Malmö on May 17, 2017Polygiene AB (publ)

Report from the annual general meeting of Wilson Therapeutics AB (publ)

On 17 May 2017, the annual general meeting of Wilson Therapeutics AB (publ) was held. Among other resolutions, the meeting resolved: · that no dividend shall be paid and that the company’s accumulated loss shall be carried forward; · to discharge the members of the board of directors and the managing director from liability; · that remuneration to the board of directors shall be paid with, in total, SEK 1,100,000, to be distributed with SEK 300,000 to the chairman of the board, SEK 200,000 to the board member Hans Schikan and with SEK 150,000 to each of the other board members, excluding Birgitte Volck, who will receive remuneration under an incentive program (see below). In addition, remuneration shall be paid with SEK 65,000 to the chairman of the audit committee and remuneration committee, respectively, and with SEK 45,000 to each of the other committee members for their work in the respective committee; · on the re-election of Dina Chaya, Andrew Kay, Genghis Lloyd-Harris, Bali Muralidhar and Hans Schikan and on the new election of Björn Odlander and Birgitte Volck as board members; · on the re-election of Andrew Kay as chairman of the board; and · on the re-election of Ernst & Young AB (with Björn Ohlsson as auditor in charge) and the election of Anna Svanberg as auditors of the company. The meeting also resolved, in accordance with the board’s proposal, to implement a new long term incentive program for certain senior executives and key employees in the Wilson Therapeutics group (“LTIP 2017”). LTIP 2017 is a three-year performance based program under which the participants will be granted, free of charge, share awards that entitle to in total not more than 135,000 shares in Wilson Therapeutics, provided that certain conditions relating to the company’s operational development and share price development are met. The meeting further resolved, in accordance with the proposal from Wilson Therapeutics’ nomination committee, to implement a similar performance based long term incentive program for the newly elected board member Birgitte Volk (“Board LTIP 2017”). Board LTIP 2017 is a three-year performance based program under which performance based share awards will be granted free of charge, which entitle to not more than 20,100 shares in Wilson Therapeutics, provided that certain conditions relating to the share price development are met. In order to ensure delivery of shares under the above-mentioned programs, the meeting further resolved to issue not more than 155,100 warrants for subscription and subsequent transfer of subscribed shares to the participants in the respective incentive program. The meeting finally resolved to authorize the board, for the period until the next annual general meeting, to adopt decisions, whether on one or several occasions and whether with or without pre-emptive rights for the shareholders, to issue new shares, provided however that such issues must not exceed ten percent of the total number of shares outstanding in the company as of the date of the annual general meeting. About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information.  For further information contact:Anders Martin-Löf, CFO, Wilson Therapeutics ABTelephone: +46 8 796 00 00Email: anders.martin-lof@wtx.se Wilson Therapeutics AB (publ)Corp. Reg. No. 556893-0357Kungsgatan 3SE-111 43 Stockholm

Annual General Meeting of AAK AB

At the Annual General Meeting of AAK AB (publ.) on May 17, 2017 the following was resolved: Board of Directors, auditor and feesThe number of directors will be seven and the trade union representatives two. The Meeting re-elected Arne Frank, Märta Schörling Andreen, Lillie Li Valeur and Marianne Kirkegaard as directors. Bengt Baron, Mikael Ekdahl and Gun Nilsson were elected as new board members. Melker Schörling and Ulrik Svensson have declined re-election. Mikael Ekdahl was elected as Chairman of the Board. Trade union representatives Leif Håkansson (IF Metall) and Annika Westerlund (PTK-L) were re-elected. The fees to the Board of Directors shall amount to a total of SEK 3,200,000 (including fees for committee work).  Re-election of the accounting firm PricewaterhouseCoopers, for a period of mandate of one year, consequently up to and including the Annual General Meeting 2018, whereby the accounting firm has informed that the authorized public accountant Sofia Götmar-Blomstedt will continue as auditor in charge. The Meeting resolved that the auditor shall be remunerated according to agreement. At the subsequent statutory board meeting it was resolved to elect Mikael Ekdahl and Märta Schörling Andreen as members of the Remuneration Committee, Mikael Ekdahl being chairman of the committee. Gun Nilsson, Lillie Li Valeur and Märta Schörling Andreen were elected members of the Audit Committee, Gun Nilsson being chairman of the committee. DividendIn accordance with the proposal of the Board of Directors, the Meeting resolved to declare a dividend of SEK 8.75 per share. Friday, May 19, 2017 was determined as record day for the payment of dividend. Payment from Euroclear Sweden AB is expected to commence on Wednesday, May 24, 2017. Nomination CommitteeHenrik Didner (Didner & Gerge fonder) and Lars-Åke Bokenberger (AMF) were re-elected and Märta Schörling Andreen (Melker Schörling AB) and Yvonne Sörberg (Handelsbanken fonder) were elected as members of the Nomination Committee in respect of the Annual General Meeting 2018. Märta Schörling Andreen was appointed Chairman of the Nomination Committee. Guidelines for remuneration to senior executivesThe Meeting adopted guidelines for remuneration to senior executives in accordance with the Board of Directors’ proposal. The Board of Directors shall be entitled to deviate from the guidelines if, in an individual case, there are particular grounds for such deviation. Incentive Program 2017/2022 for all employeesIn accordance with the proposal of the Board of Directors, the Meeting resolved on a long-term incentive program (“Incentive Program 2017/2022”) including resolutions on an issue and allotment of convertible bonds for implementation of a convertible program for all employees within the AAK group, as well as an issue of subscription warrants for implementation of a subscription warrants program for all employees, which is linked to the convertible program. The convertible loan has a maximum nominal value of SEK 25,000,000, and the subscription price for each convertible bond shall be equal to its nominal value, which shall correspond to the market value of the convertible bonds. With deviation from the shareholders’ preferential rights, the right to subscribe for the convertible bonds shall be granted to employees of the AAK group. All participants of the convertible program are entitled to subscribe for a maximum amount of SEK 150,000. The conversion price shall correspond to 133 percent of the volume weighted average price for the share in the company during the period May 18, 2017 – June 1, 2017, but not lower than the share’s quota value. The convertible bonds may be converted into new shares in AAK AB quarterly during the period September 15, 2020 – August 31, 2021. The convertible bonds shall carry annual interest from September 15, 2017 equivalent to STIBOR 3M plus an interest margin established by an independent valuation institute so that the market value of the convertibles corresponds to their nominal amount. The loan is due for payment on September 15, 2021, in so far as conversion has not occurred before. The Meeting further resolved to issue a maximum of 145,000 subscription warrants entitling to subscription for a corresponding number of new shares in AAK AB by which the share capital may be increased by a total of maximum SEK 1,450,000. All participants of the convertible program shall, with deviation from the shareholders’ preferential rights, be entitled to subscribe for four (4) subscription warrants for each convertible bond that the participant has subscribed for in the convertible program. The subscription warrants shall be issued at a subscription price corresponding to the market value. Subscription for shares in AAK AB by exercise of the subscription warrants may take place quarterly during the period September 1, 2020 – August 31, 2022. The subscription price per share shall correspond to 133 percent of the volume weighted average price for the share in the company during the period May 18, 2017 – June 1, 2017, but not lower than the share’s quota value. The increase of AAK AB’s share capital will at full subscription and conversion of the convertible bonds, respectively, based on a conversion price of SEK 838 (corresponding to 133 percent of SEK 630), amount to approximately SEK 300 000, which, at full conversion of the convertible bonds, corresponds to a dilution of approximately 0.07 percent of the share capital and the total number of votes. At full subscription and full exercise of the subscription warrants, the share capital may be increased by a total of maximum SEK 1,450,000, which is equivalent to approximately 0.3 percent of the company’s present share capital. This corresponds to a total dilution of maximum approximately 0.3 percent in relation to the share capital on a fully diluted basis, calculated as the number of new shares in proportion to the number of existing and new shares. Warrants Program series 2017/2022:2 for senior executives and key employeesIn accordance with the proposal of the Board of Directors, the Meeting further resolved on a long-term incentive program for senior executives and key employees within the AAK group including resolutions on an issue of maximum 1,220,000 subscription warrants entitling to subscription for a corresponding number of new shares in AAK AB by which the share capital may be increased by a total of maximum SEK 12,200,000 (“Warrants Program series 2017/2022:2”). The issue shall, with deviation from the shareholders’ preferential rights, be granted to the wholly-owned subsidiary AAK Invest AB, at a subscription price corresponding to the market value. The subscription warrants shall be transferred by AAK Invest AB to senior executives and key employees within the AAK group at a price corresponding to the market value at the time of transfer. The Board of Directors of AAK AB shall be entitled to decide on the allotment of subscription warrants to approximately 100 senior executives and key employees within the group. Senior executives and key employees who participate in the Warrants Program series 2017/2022:2 may not participate in the Incentive Program 2017/2022 and vice versa. Subscription for shares in AAK AB by exercise of the subscription warrants may take place during the period September 1, 2020 – August 31, 2022. The subscription price per share shall correspond to 133 percent of the volume weighted average price for the share in the company during the period May 18, 2017 – June 1, 2017, but not lower than the share’s quota value. At full subscription and full exercise of the subscription warrants, the share capital may be increased by a total of maximum SEK 12,200,000, which is equivalent to approximately 2.9 percent of the company’s present share capital. This corresponds to a total dilution of maximum approximately 2.8 percent in relation to the share capital on a fully diluted basis, calculated as the number of new shares in proportion to the number of existing and new shares. Share splitA proposal of share split 2:1 was presented to the Meeting. The Meeting resolved to not adopt the proposal. Comments from the CFO and Acting CEOCFO and Acting CEO Fredrik Nilsson reported on the company’s operations during the year of 2016 and the first quarter of 2017. Chief Marketing Officer Anne Mette Olesen presented AAK’s progress in the sustainability area and the new company program The AAK Way. “Based on AAK’s customer value propositions for health and reduced costs, and our customer product co-development and solutions approach, we continue to remain prudently optimistic about the future. The main drivers are the continued positive underlying development in Food Ingredients and a continued improvement in Chocolate & Confectionery Fats”, commented Fredrik Nilsson, CFO and Acting CEO. The presentation can be found in its entirety on the company’s website, www.aak.com.  For further information, please contact:  Fredrik NilssonCFO and Acting CEOMobile: +46 708 95 22 21E-mail: fredrik.nilsson@aak.com  This information is information that AAK AB (publ.) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 4:45 p.m. CET on May 17, 2017.  AAK is a leading provider of value-adding vegetable oils & fats. Our expertise in lipid technology within foods and special nutrition applications, our wide range of raw materials and our broad process capabilities enable us to develop innovative and value-adding solutions across many industries – Chocolate & Confectionery, Bakery, Dairy, Special Nutrition, Foodservice, Personal Care, and more. AAK’s proven expertise is based on more than 140 years of experience within oils & fats. Our unique co-development approach brings our customers’ skills and know-how together with our own capabilities and mindset for lasting results. Listed on the NASDAQ OMX Stockholm and with our headquarters in Malmö, Sweden, AAK has 20 different production facilities, sales offices in more than 25 countries and more than 3,000 employees. We are AAK – The Co-Development Company. 

Allianz Worldwide Partners Recognized for Outstanding Public Relations Programs at the 70th Virginia Public Relations Awards

Global insurance provider Allianz Worldwide Partners  won the top award in the category of Blogger Campaigns at the 70th Virginia Public Relations Awards hosted by the Public Relations Society of America Richmond Chapter.  The company won the Capital Award of Excellence for its Allianz Travel Insurance Three-tiered Blogger Campaign. The award is the company’s second win this year for outstanding influencer marketing programs.  Earlier this year it won a Gold trophy in the category of PR Campaign – Influencer Marketing during the 60th annual Adrian Awards, presented in February by The Hospitality Sales and Marketing Association International (HSMAI).   Allianz Worldwide Partners and its marketing communications agency Finn Partners, were recognized for creating a three-tiered influencer marketing campaign, which incorporated brand ambassadors, travel influencers and content partnerships to raise awareness of its travel insurance brand. “I’m honored to accept this Capital Award on behalf of the talented group of travel influencers we’ve worked with to achieve our goal in raising awareness of the importance of travel insurance,” said Daniel Durazo, director of communications at Allianz Worldwide Partners USA. Travel influencers were tasked to produce and publicize creative content for Allianz Travel Insurance, bringing personality to the brand and elevating travel insurance to a must-have travel accessory when planning vacations. Allianz’s influencer program included well-known travel writers, bloggers and influencers such as Lee Abbamonte, the youngest American to visit every country. “As a brand ambassador for Allianz Travel Insurance, I have the exciting role of finding new, creative ways to bring attention to travel insurance – which is an essential element for ensuring peace of mind when traveling,” said Lee Abbamonte, travel blogger at LeeAbbamonte.com. Allianz Global Assistance branded travel insurance* is offered through most major U.S. airlines, leading travel agents, online travel agencies, other travel suppliers and directly to consumers. For more information please visit: http://www.allianztravelinsurance.com.  # # # Allianz Worldwide Partners USA  Allianz Worldwide Partners USA (AGA Service Company) is a leading consumer specialty insurance and assistance company.  We provide insurance to over 25 million customers annually and are best known for our Allianz Travel Insurance plans. In addition to travel insurance, we offer Allianz Global Assistance branded tuition insurance, event ticket protection, registration protection for endurance events and unique travel assistance services such as international medical assistance and concierge services. The company also serves as an outsource provider for in-bound call center services and claims administration for property and casualty insurers and credit card companies.  To learn more about Allianz Travel Insurance, please visit allianztravelinsurance.com or Like us on Facebook at Facebook.com/AllianzTravelInsuranceUS.  * - Terms, conditions, and exclusions apply to all plans.  Plans are available only to U.S. residents.  Not all plans are available in all jurisdictions.  For a complete description of the coverage and benefit limits offered under your plan, carefully review your plan’s Letter of Confirmation/Declarations and Certificate of Insurance/Policy.  Insurance coverage is underwritten by BCS Insurance Company (OH, Administrative Office: Oakbrook Terrace, IL), rated "A-" (Excellent) by A.M. Best Co., under BCS Form No. 52.201 series or 52.401 series, or Jefferson Insurance Company (NY, Administrative Office: Richmond, VA), rated "A+" (Superior) by A.M. Best Co., under Jefferson Form No. 101-C series or 101-P series, depending on state of residence.  Allianz Global Assistance and Allianz Travel Insurance are brands of AGA Service Company.  AGA Service Company is the licensed producer and administrator of these plans and an affiliate of Jefferson Insurance Company.  The insured shall not receive any special benefit or advantage due to the affiliation between AGA Service Company and Jefferson Insurance Company.  Non-insurance benefits/products are provided and serviced by AGA Service Company.

ANNUAL GENERAL MEETING IN BONG AB (publ)

Board of Directors and Auditors Re-election of Mikael Ekdahl, Stéphane Hamelin, Eric Joan, Christian Paulsson and Helena Persson and newly election of the company’s CEO Håkan Gunnarsson and Stefan Lager as ordinary board members. Christian Paulsson was elected as Chairman of the Board. Directors’ fees were set at an amount of SEK 300,000 to the Chairman and SEK 150,000 to each of the other board members not employed with the company. Fees for committee work will be paid to the Chairman of the Audit Committee with SEK 100,000 and SEK 50,000 to each member. Election of the accounting firm PricewaterhouseCoopers AB for a one year period of mandate, consequently up to and including the AGM 2018, whereby the accounting firm has informed that authorised public accountant Lars Nilsson will be the auditor in charge. Fees to the auditors will be paid as per agreement. Disposition of result The Meeting adopted the proposal of the Board of Directors that no dividend is to be distributed for the financial year 2016 and that the results of the company of SEK 975,375,629 in total, including this year’s result of SEK 294,050,944 should be carried forward. Nomination Committee Re-election of Stéphane Hamelin (Holdham S.A.), Ulf Hedlundh (Svolder Aktiebolag) and Christian Paulsson (Paulsson Advisory AB) as members of the Nomination Committe for the AGM 2018. Stéphane Hamelin was elected Chairman of the Nomination Committee. Remuneration and Audit Committee At the subsequent statutory board meeting Stéphane Hamelin, Mikael Ekdahl and Christian Paulsson were elected as members of the Remuneration Committee for the period up to the next statutory board meeting. Further, Mikael Ekdahl and Christian Paulsson were elected as members of the Audit Committee for the same period. Guidelines for remuneration to senior executives The AGM resolved to establish guidelines for remuneration to senior executives principally entailing that remuneration to senior executives shall consist of fixed salary, variable remuneration, other benefits and pension and that the aggregate remuneration shall be in accordance with market conditions and competitive. The variable part of the salary shall have a pre-deterimined cap and may as a fundamental principle never exceed 60 per cent of the fixed annual salary. The variable part is based on earnings and cash flow as well as individual qualitative goals. Variable remuneration shall not qualify for pension. Pension benefits shall primarily be fee based, but can also for legal reasons be income based, although not at the group management level. The retirement age is 65 years. The group management’s employment contracts include provisions governing remuneration and termination of employment. According to these agreements, employment can ordinarily cease on notice of termination by the employee within a period of notice of 4-12 months and on dismissal by the company within a period of notice of 6-18 months. On dismissal by the company, the period of notice and the period during which compensation is payable shall not together exceed 24 months. The guidelines in full are published on the company’s website. Kristianstad, 17 May 2017 Bong AB (publ)The Board of Directors For further information, contact Håkan Gunnarsson, CEO, Bong AB. Telephone (switchboard) +46 44 20 70 00. Bong is one of the leading providers of specialty packaging and envelope products in Europe and offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.1 billion and about 1,500 employees in 15 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its shares are listed on Nasdaq Stockholm (Small Cap).

Mölnlycke opens new manufacturing plant in Havirov, Czech Republic

Gothenburg, Sweden – 18 May 2017  Mölnlycke, a world-leading medical products and solutions company, is pleased to announce yesterday’s opening of a new manufacturing plant in Havirov, Czech Republic. The new plant is Mölnlycke’s largest investment to date, EUR 67 million, and will help create value for customers with cost-effective and safe surgical solutions. It will increase the logistic solutions flexibility, as Mölnlycke will be assembling trays at order and sterilize them in-house before shipping either directly or via distribution centres to customers depending on customer profile and needs. The products manufactured at the factory will sell worldwide from day one, and are currently authorized for sale in 60 countries. Present at the opening ceremony were, among others, Viktoria Li, Ambassador of Sweden to the Czech Republic, Ivo Vondrak, Regional Governor of the Moravian-Silesian region, Jana Feberova, Mayor of Havirov, Gunnar Brock, Chairman of Mölnlycke as well as other key representatives from national- and local authorities. Richard Twomey, CEO of Mölnlycke, comments: “We are excited about the opening of a new manufacturing plant in the Czech republic. Mölnlycke is growing fast and this investment will secure our ability to meet the increasing demand from our customers. The new plant is also an important step on a larger journey for Mölnlycke to advance performance in healthcare within our three focus areas: Wound management, Prevention, and Surgical solutions.” Emmanuel Chilaud, General Manager, Procedure tray factories, comments:  “We know from experience working with hospitals that one size does not fit all; every procedure is different and each hospital has its preferred configuration. We are now offering health care professionals a wider range of truly customized surgical solutions. There is no limit to the number of combinations of trays. We offer tailor made solutions, and can customize a procedure tray to match, in one pack. With truly customized surgical procedure trays, Mölnlycke can ensure high-quality care and patient safety through accuracy and consistency for every procedure set-up.”  For more information, please contact:  Bodil Czarnecki Bengtsson, Global Manager Corporate Communicationsbodil.czarnecki@molnlycke.com+46 (0) 31 722 30 37 Notes for the editors:  Mölnlycke is a world-leading medical solutions company. We design and supply solutions to enhance performance at every point of care – from the hospital to the home. We specialise in: · Wound management: including dressings with Safetac® such as Mepitel® and Mepilex® and Avance® for negative pressure wound therapy. · Preventing pressure ulcers: with Mepilex® Border used prophylactically and devices to help turn and re-position patients. · Surgical solutions: including Mölnlycke Trays, Barrier® surgical drapes, HiBi® antiseptics and Biogel® surgical gloves. Mölnlycke was founded in 1849. Nowadays our solutions are available in around 100 countries; we are the number one global provider of advanced wound care and single-use surgical products; and we are Europe's largest provider of customised trays.  Our headquarters are in Gothenburg, Sweden and we have about 7,500 employees around the world.For more information, please visit www.molnlycke.com.

Proposal of remedies to meet requirements of the EU Merger Regulation

On April 12, 2017 Nordic Capital Fund VIII, currently the indirect majority shareholder in Lindorff, notified the European Commission of the intended combination of Intrum Justitia and Lindorff. Based on its initial investigation, the European Commission has informed the parties of potential competition concerns in five Nordic/Baltic markets, relating to both debt collection and debt purchasing in each market. The parties have therefore proposed a divestment of Lindorff’s entire business in Denmark, Estonia, Finland and Sweden as well as Intrum Justitia’s entire business in Norway. In Sweden, Denmark, Norway and Finland, the units proposed to be divested are smaller than the units that will remain in the combined group. The European Commission will now assess whether the divestment of the proposed units will address its concerns, and this assessment may include a market test. We expect a final decision from the European Commission no later than June 12 2017. The combined group would have pro-forma earnings (EBITDA, excluding impact of synergies and non-recurring items) of approximately SEK 5.0 billion for 2016, of which an estimated 12%-13% derives from the five units proposed to be divested. The combination of Intrum Justitia and Lindorff has been estimated to result in total annual cost synergies in 3-4 years of approximately SEK 800 million. The five units proposed to be divested account for an estimated 30% of the estimated total cost synergies. In line with earlier communication, the combination of Intrum Justitia and Lindorff is also expected to result in revenue synergies, which are not included in the SEK 800 million cost synergy estimate. The units proposed to be divested together have approximately 850 employees. For more information, please contact: Lars Lundquist, Chairman of the BoardTel: + 46 8 546 102 02 Mikael Ericson, CEO & PresidentTel: + 46 8 546 102 02 Erik Forsberg, CFOTel: +46 8 546 102 02 Annika Billberg, Communications DirectorTel: + 46 702 67 97 91 About Intrum Justitia: Intrum Justitia offers comprehensive services, including purchase of receivables, designed to measurably improve clients’ cash flows and long-term profitability. Founded in 1923, Intrum Justitia has some 4,200 employees in 21 markets. Consolidated revenues amounted to SEK 6.1 billion in 2016. Intrum Justitia AB is listed on Nasdaq Stockholm since 2002. For further information, please visit www.intrum.com About Lindorff: Lindorff has been in the business of helping people manage credit for over 100 years. Its headquarters are located in Oslo, Norway, the same city as Eynar Lindorff founded the company back in 1898. Today it has 4,400 people in 12 countries across Europe helping customers back to a life of sustainable spending. Nordic Capital Fund VIII is a majority shareholder in the company which offers services within debt collection and debt purchase as well as payment and invoicing services. In 2016 Lindorff generated EUR 647 million in net revenue (2015 EUR 534 million). For further information, please visit www.lindorff.com About Nordic Capital: Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. The Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory entities in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com    

Oncopeptides AB Interim Report January - March 2017

SUMMARY OF Q 1  January 1st – March 31st 2017 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period was 62.1 (loss: 15.2) MSEK · Loss per share, before and after dilution, was 1.89 (loss: 0.92) SEK · On March 31st, cash and cash equivalents amounted to 611.6 (20.1) MSEK Significant events during the period January 1st to March 31st 2017 · Oncopeptides was listed in the Mid Cap segment on Nasdaq OMX Stockholm, raising 695.0 MSEK (approx. 77 MUSD) before transaction costs · On March 15th ‘Intention to grant’ letter was received from the European Patent Office extending the patent life for Ygalo® in Europe to 2032 without extensions FINANCIAL OVERVIEW OF THE GROUP (SEK thousand): +--------------------------+---------+---------+---------+|Financial overview of the | | | ||group (SEK thousand) | | | |+--------------------------+---------+---------+---------+| | 2017| 2016| 2016|+--------------------------+---------+---------+---------+| |Jan - Mar|Jan - Mar|Jan - Dec|+--------------------------+---------+---------+---------+|  | | | |+--------------------------+---------+---------+---------+|Net sales | -| -| -|+--------------------------+---------+---------+---------+|Operating loss | -62,083| -15,244| -114,482|+--------------------------+---------+---------+---------+|Loss before tax | -62,083| -15,244| -114,446|+--------------------------+---------+---------+---------+|Loss for the period | -62,083| -15,244| -114,446|+--------------------------+---------+---------+---------+|  | | | |+--------------------------+---------+---------+---------+|Earnings per share before | -1.89| -0.92| -4.88||and after dilution (SEK)  | | | |+--------------------------+---------+---------+---------+|  | | | |+--------------------------+---------+---------+---------+|Cash flow from operating | -67,637| -13,130| -104,262||activities | | | |+--------------------------+---------+---------+---------+|Cash and cash equivalents | 611,599| 20,111| 40,251||at the end of the period | | | |+--------------------------+---------+---------+---------+|  | | | |+--------------------------+---------+---------+---------+|Research & development | 76%| 86%| 78%||costs/operating expenses %| | | |+--------------------------+---------+---------+---------+ FINANCIAL CALENDARAnnual General Meeting 2017 May 18th 2017Interim Report Q2 2017 August 25th 2017Interim Report Q3 2017 November 15th 2017Full Year Report 2017 February 22nd 2018 For further information, please contact:Jakob Lindberg, CEO for Oncopeptides ABE-mail: jakob.lindberg@oncopeptides.seTel: +46 8 615 20 40 Rein Piir, Head of Investor Relations for Oncopeptides ABE-mail: rein.piir@oncopeptides.seTel: +46 70 853 72 92 This information that Oncopeptides AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the persons above, 08.00 am CET on May 18th 2017. About OncopeptidesOncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company the focus has primarily been on the development of the lead product candidate Ygalo, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

NeuroVive Pharmaceutical AB Interim report January - March 2017

Business operations Significant events January-March 2017 • Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company’s new generation of sanglifehrin-based compounds in the NVP024 project. • The business operations of the Taiwanese subsidiary were sold to the Taiwanese shareholders in order to reallocate research resources to the Parent Company. • Collaboration agreement signed with a prestigious US research team in mitochondrial medicine for the NVP015 project focused on mitochondrial genetic disorders. • The mitochondrial myopathy indication – new project added to the portfolio, NVP025. Collaboration agreement was signed with Karolinska University Hospital. Important events after the end of the period • The anti-fibrotic effects of NV556 in NASH were confirmed in an additional experimental model. The preclinical results were presented at the International Liver Congress™. • A clinical development project for genetic mitochondrial disorders was in-licensed from Yungjin Pharm Corporation Ltd. Financial information First quarter (January-March 2017) • Net revenues were SEK 27,000 (0) and other operating income was SEK 63,000 (46,000) • Loss before tax was SEK 21,390,000 (loss: 10,916,000) • Loss per share* was SEK 0.40 (loss: 0.35) • Diluted loss per share** amounted to SEK 0.40 (loss: 0.35) * Profit/loss for the period divided by average number of shares before dilution at the end of the period.** Profit/loss for the period divided by average number of shares after dilution at the end of the period Please find the complete interim report attached below. This information is information that NeuroVive Pharmaceuticals (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 18 May 2017. About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production. NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project entering clinical Phase I (KL1333). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenPhone: 046-275 62 20 (switchboard)ir@neurovive.comwww.neurovive.com

Interim report for the first quarter 2017: Strong start to the year creates good conditions for the future

CEO’s comments 2017 has begun in the best possible way, with continuing strong growth and good profitability. Our Q1 revenue amounted to SEK 41 million, an increase of 912% compared with the same period the previous year, while EBITDA amounted to SEK 25 million in the first quarter of 2017, which was a significant increase from the same period the previous year. The operating margin also increased to 61%.   Since the acquisition of Highlight Media was finalised, we have been working hard to systematically improve ourselves at all levels of the organisation. The initiatives we have implemented this year have produced direct effects in virtually all markets. We have seen an improvement in our search engine rankings for selected high-value keywords. This has meant that we have also seen an increase in incoming traffic to our sites and consequently an increase in leads (traffic from our sites to the iGaming operators). The impact on revenue normally comes a little later.    There has been a clearly positive start to the second quarter. Revenue and operating profit have been in line with the first quarter, even though the second quarter is normally the weakest quarter in the year due to seasonal variations. In terms of the increase in leads in April, the underlying trend is even more distinct. This means that I feel very confident in our ability to deliver full-year results for 2017 that will show continuing strong earnings growth. We have good momentum in our daily machinery, we have a charted path for 2017 and I will continue to work on our clear growth strategy. In more concrete terms, this also means that we want to continue to play an active role in the consolidation taking place in the market. There is no doubt that we have interesting times ahead of us!   Marcus Teilman, President and CEO 

Less food waste reduces climate change

Food waste currently causes a large proportion of the overall environmental impact in the Nordics and needs to be reduced throughout the food supply chain—by manufacturers, wholesalers, suppliers, stores, restaurants, catering kitchens and households. Coor is one of the Nordics’ leading FM providers, and food & beverage is one of the company’s biggest service areas. Coor currently operates over 120 restaurants in Sweden, Norway and Denmark. Coor is now introducing a program aimed at measuring food waste across all its restaurant facilities. Food waste occurs in the food preparation process in kitchens, during serving as well as at the dish station. ”We’ve previously measured food waste in a number of our restaurants, and are now introducing a uniform measurement instrument across all operations. We’re starting by measuring and following-up our food service provision, and the next step will be to set targets for individual restaurants. The objective is to reduce food waste by 20 per cent in one year. To achieve that, changes will need to be made to the food production process, and we’ll need to encourage our end customers to only take as much food as they’ll eat,” commented Per Åhrén, Service Excellence Owner, Food & Beverage, at Coor. Food waste will be measured on a daily basis and entered into a dedicated system developed by Coor. ”Like all responsible companies, we’re working to reduce our environmental impact through a range of measures. The raw materials handling process is one of five major environmental factors, and this is a significant step in the right direction in terms of reducing our environmental impact,” commented Åsvor Brynnel, Communications and Sustainability Director at Coor. Read more about Coors´environmental efforts in the Sustainability Report 2016 at www.coor.com. For more information, images etc., please visit www.coor.com or contact:Per Åhrén, Service Excellence Manager, Coor  +46 10 559 59 54    per.ahren@coor.comÅsvor Brynnel, Communications and Sustainability Director +46 10 559 54 04             asvor.brynnel@coor.com

Elocta® approved in the Kingdom of Saudi Arabia for the treatment of haemophilia A

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.  Elocta is the first extended half-life and recombinant factor VIII Fc fusion protein therapy approved for the treatment of haemophilia A in Saudi Arabia.  “The approval of Elocta in Saudi Arabia is an important development for the haemophilia community in the Middle East and will enable physicians to offer their patients a wider range of treatment options.” says Ahmad Abu-Dahab, Regional Director Middle East, & Turkey. “We will now focus on ensuring access to Elocta for people living with haemophilia A across other Middle Eastern states.” says Ebrahim Al-Hagiri, Regulatory & Patient Access Manager Middle East & Turkey “This is a very important milestone to ensure that patients with haemophilia A have an early and sustainable access to this bleed prevention treatment.” Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages. The Saudi Arabia approval was based on data from Elocta’s pivotal, phase 3 A-LONG clinical study, which demonstrated the efficacy, safety and pharmacokinetics of efmoroctocog alfa in previously treated males 12 years of age and older with severe haemophilia A, and from the phase 3 Kids A-LONG clinical study, which demonstrated the efficacy and safety of efmoroctocog alfa in previously treated male children with haemophilia A under 12 years of age. ---- About haemophilia AHaemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually, and more rarely in females. The World Federation of Hemophilia estimates that approximately 150,000 people are currently diagnosed with haemophilia A world-wide[i] .People with haemophilia A experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Prophylactic injections of factor VIII can temporarily replace the clotting factors that are needed to control bleeding and prevent new bleeding episodes[ii] . The World Federation of Hemophilia (WFH) recommends prophylaxis as the optimal therapy as it can prevent bleedings and joint destruction[iii] . About Elocta®Elocta® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body. While Fc fusion technology has been used for more than 15 years, Sobi and Bioverativ have optimised the technology and are the first companies to utilise it in the treatment of haemophilia. Elocta is manufactured using a human cell line in an environment free of animal and human additives. Elocta is approved and marketed by for the treatment of haemophilia A in the European Union, Switzerland, Iceland, Liechtenstein, Norway and Kuwait. It is approved and marketed as ELOCTATE® by Bioverativ  in the United States, Japan and Canada. It is also approved in  Australia, New Zealand, Brazil and other countries, and Bioverativ has marketing rights in these regions. As with any factor replacement therapy, allergic-type hypersensitivity reactions and development of inhibitors may occur in the treatment of haemophilia A. Inhibitor development has been observed with Elocta, including in previously untreated patients. Note that the indication for previously untreated patients is not included in the EU Product Information  for Elocta. About the Sobi™ and Bioverativ collaborationSobi and Bioverativ collaborate on the development and commercialisation of Alprolix® and Elocta/ELOCTATE. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Bioverativ has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory, and has manufacturing responsibility for Elocta and Alprolix. Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts, USA.  During a temporary, transition period, which includes time to allow Bioverativ to establish certain licenses and consents related to ELOCTATE and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products. About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. For more informationplease contact  Media relations   Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor Relations+ 46 708 73 40 95, + 46 +1 347 224 0819, +1 212 5798 697 31 74   0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  ---------------------------------------------------------------------- [i]  World Federation of Hemophilia, Annual Global Survey 2015, published in October 2016. Available at: http://www.wfh.org/en/data-collection [ii]  World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: June 17, 2016  [iii]  Guideline for the management of hemophilia, World Federation of Hemophilia, 2nd edition, http://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed on December 2015 

Play’n GO victorious at 8th Women in Gaming Awards

18th May, 2017 - Award-winning slots specialist Play’n GO has won the Diversity Award at the Women in Gaming Awards 2017 (WIGs). Play’n GO personnel were in-attendance to receive the distinguished award at a ceremony held at the Savoy Hotel, London last week, where they were also nominated for four other awards. The judging panel were impressed by the supplier’s commitment to diversity within the company, with 46% of its management positions currently occupied by women and all employees rewarded solely for their job acumen and success, as opposed to any other factor. Johan Törnqvist, CEO at Play’n GO, said: “This award is testament to all of our employees at Play’n GO who have helped make our working environment conducive to creativity and innovative thinking. “Our truly diverse team has helped create a dynamic working environment which will ensure we remain at the forefront of the gaming industry for the foreseeable future.” The WIGs look to its 9thedition in 2018 as they continue to promote the outstanding contribution female employees have made to their respective businesses and the gaming industry. Play’n GO was nominated across four other categories on the night, including Employee of the Year, Leader iGaming, Team of the Year and Best Place to Work, and look to further success in the awards in future as they add to their burgeoning team within existing offices and in their newest London site.

Nord Stream Awards Contract for External Inspection of the Pipeline to MMT

The scope of work, involving approximately 150 days for 2017, includes visual and instrumental inspection of the pipelines with remotely operated vehicles (ROVs) over the entire length of the route. The trenched sections and cable crossings of the pipeline will also be inspected. The survey will mainly be conducted from the vessel Stril Explorer.The purpose of these surveys is to acquire data on the condition of both pipeline strings and associated installations. This information is used in the continued assessment of the pipelines’ integrity, and will complement the data generated in earlier inspection campaigns. MMT Sweden’s founder Ola Oskarsson commented: “We are very proud to be chosen to conduct the important inspections of this great infrastructure project and bring our new technology to the Baltic Sea. In cooperation with our partner, Reach Subsea, we will support Nord Stream’s safe and environmentally sound energy transport to Europe.” Reach Subsea’s founder and CEO Jostein Alendal added: “This three-year contract award is a result of the excellent operational performance in offshore survey carried out in close cooperation with our partner MMT Sweden over the past years.” Managing Director of Nord Stream AG Alexey Zagorovskiy commented: “Reliability, safety and professional management are important for us as a company, and also in terms of choosing a supplier. We hope that our cooperation with MMT will be successful and mutually beneficial.” For further information, please contact:Email: press@nord-stream.comPhone: +417669316 Notes to editorsNord Stream AG is an international joint venture established for the planning, construction and operation of the twin offshore gas pipelines through the Baltic Sea. Russian OAO Gazprom holds a 51 per cent stake in the joint venture. The German companies BASF SE/Wintershall Holding GmbH and PEG Infrastruktur AG (PEGI/E.ON subsidiary), hold 15.5 per cent each, and the Dutch gas infrastructure company N.V. Nederlandse Gasunie along with the leading French energy provider ENGIE, each hold a 9 per cent stake. Nord Stream’s head office and operations centre are both in Zug, Switzerland. Nord Stream’s natural gas pipelines through the Baltic Sea have the capacity to transport 55 billion cubic metres (bcm) of Russian gas a year to the EU, for at least 50 years. Both lines run in parallel for 1,224 kilometres from Portovaya Bay, near Vyborg on the Russian Baltic Sea coast, to Lubmin, Germany. Each pipeline comprises some 100,000 24-tonne concrete-weight-coated steel pipes laid on the seabed along the precise route approved by the authorities of the five countries through whose waters the pipelines pass. Construction of the first Nord Stream Pipeline started in April 2010, and both lines were completed and on-stream in October 2012, on schedule and on budget. http://www.nord-stream.com/ Specialising in high resolution subsea surveys, MMT is the solution to your marine surveying needs. We collect, process and visualise the conditions of the seabed. We offer assured surveys in bathymetric, geophysical and geotechnical services, specialising in the oil & gas, hydrography and renewable energy & marine cable sectors. Our competence and services will supply you with the relevant information, designed to fit your planning processes of your offshore infrastructure projects. Contact:Stefan Eliasson, CEO, MMTEmail: stefan.eliasson@mmt.sePhone: +46 (0)705 67 38 99 Ola Oskarsson, Founder & CTO, MMTEmail: ola.oskarsson@mmt.sePhone: +46 (0)708 52 78 85 Reach Subsea is a provider of subsea services, mainly related to WROV (work class remotely operated vehicles) operations performed by highly qualified personnel, within IMR (inspection, maintenance and repair), survey, construction support and decommissioning. Reach Subsea was established in 2008 and is listed on Oslo Stock Exchange. Contact:Jostein Alendal, CEO, ReachSubsea ASEmail: jal@reachsubsea.noPhone: +47 928 80 412

Correction: Proposal of remedies to meet requirements of the EU Merger Regulation

On April 12, 2017 Nordic Capital Fund VIII, currently the indirect majority shareholder in Lindorff, notified the European Commission of the intended combination of Intrum Justitia and Lindorff. Based on its initial investigation, the European Commission has informed the parties of potential competition concerns in five Nordic/Baltic markets, relating to both debt collection and debt purchasing in each market. The parties have therefore proposed a divestment of Lindorff’s entire business in Denmark, Estonia, Finland and Sweden as well as Intrum Justitia’s entire business in Norway. In Sweden, Denmark, Norway and Finland, the units proposed to be divested are smaller than the units that will remain in the combined group. The European Commission will now assess whether the divestment of the proposed units will address its concerns, and this assessment may include a market test. We expect a final decision from the European Commission no later than June 12 2017. The combined group would have pro-forma earnings (EBITDA, excluding impact of synergies and non-recurring items) of approximately SEK 5.0 billion for 2016, of which an estimated 12%-13% derives from the five units proposed to be divested. The combination of Intrum Justitia and Lindorff has been estimated to result in total annual cost synergies in 3-4 years of approximately SEK 800 million. The five units proposed to be divested account for an estimated 30% of the estimated total cost synergies. In line with earlier communication, the combination of Intrum Justitia and Lindorff is also expected to result in revenue synergies, which are not included in the SEK 800 million cost synergy estimate. The units proposed to be divested together have approximately 850 employees. For more information, please contact: Lars Lundquist, Chairman of the BoardTel: + 46 8 546 102 02 Mikael Ericson, CEO & PresidentTel: + 46 8 546 102 02 Erik Forsberg, CFOTel: +46 8 546 102 02 Annika Billberg, Communications DirectorTel: + 46 702 67 97 91 About Intrum Justitia: Intrum Justitia offers comprehensive services, including purchase of receivables, designed to measurably improve clients’ cash flows and long-term profitability. Founded in 1923, Intrum Justitia has some 4,200 employees in 21 markets. Consolidated revenues amounted to SEK 6.1 billion in 2016. Intrum Justitia AB is listed on Nasdaq Stockholm since 2002. For further information, please visit www.intrum.com About Lindorff: Lindorff has been in the business of helping people manage credit for over 100 years. Its headquarters are located in Oslo, Norway, the same city as Eynar Lindorff founded the company back in 1898. Today it has 4,400 people in 12 countries across Europe helping customers back to a life of sustainable spending. Nordic Capital Fund VIII is a majority shareholder in the company which offers services within debt collection and debt purchase as well as payment and invoicing services. In 2016 Lindorff generated EUR 647 million in net revenue (2015 EUR 534 million). For further information, please visit www.lindorff.com About Nordic Capital: Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. The Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory entities in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com    

World’s largest mixed-reality display unveiled with 3D rocket launch

Copenhagen, 18 May 2017: The new breakthrough patent-pending display technology was recently unveiled to a small audience in a surprise demonstration at the national aquarium in Copenhagen, Denmark. Here the new display showed a realistic 3D rocket launch taking place about two kilometres out on the water. A video crew captured the reaction from the spectators stunned by the realistic and unexpected lift-off taking place in front of their eyes, highlighting DeepFrame’s future potential.  “Since 2008, we have been working on mixed-reality solutions that makes it possible for several viewers to share the same visual 3D experience embedded in the real physical world without the use of glasses. With DeepFrame, we have finally solved this challenge making it possible to erase the line between fiction and reality. Now you could potentially be seeing a lifelike 3D version of King Kong climbing the building across from your office window,” says Peter Simonsen, Co-founder and R&D Director, Realfiction. The breakthrough technology behind DeepFrame enables large-scale 3D visuals looking like holograms in 4K resolution seen through what looks like a window-frame. Unlike other mixed-reality solutions currently under development by other companies, DeepFrame does not require spectators to wear any glasses or other eyewear to view the true-to-life animations. This makes it possible to create visuals that are integrated directly in to everyday social situations, where several people can share the same experience as a social event. Endless possibilities for new mixed-reality experiences Realfiction is a Danish company that have been working with companies such as Louis Vuitton, Tag Heuer and Samsung in the mixed-reality space since 2008, where display technology adds an extra digital layer to the world in real time, thereby enhancing reality. The market for mixed-reality solutions is estimated to reach a yearly revenue of USD 80 billion in 2025, according to research by Goldman Sachs Group, Inc. The DeepFrame series of large mixed-reality screens offer many applications that apply to a broad range of industries. For example, the displays are expected to be used in theme parks, retail spaces, exhibitions, construction projects and in the foreseeable future also consumer products. “We are very excited to announce DeepFrame and expect to offer it commercially for companies that want to create extraordinary viewing experiences from August on. This technology enables companies in nearly any industry to present new content and real-life experiences to their audiences, and in the very near future, we also expect it to become a popular technology in consumer products,” says Clas Dyrholm, CEO, Realfiction. Realfiction’s existing display solution, Dreamoc, has already been a large success in the retail and exhibition space, but is limited by its form factor. With DeepFrame size is no longer an issue, as the displays can reproduce visuals of virtually any size such as a new bridge, a car, a rebuilt castle ruin or a real-size visualisation of a spaceship hovering above the city skyline. DeepFrame is based on a combination of well-known technologies, refined through high technical quality and precision in the production phase. The image from a curved video screen is deflected and enlarged in a custom-made glass optic. This glass optic, in its current form of 64 inches (115x115cm) is perceived as a clear transparent window. The other side of the window shows the reality you are in, combined with the projection of the image from the video screen. Because the glass optics also greatly magnify the image, a screen of just 65 inches, can create a projected animation that covers an area of several square miles. The patent pending technology is developed by Realfiction. The manufacturing process of the optics is as complex as making lenses for deep space telescopes. Realfiction’s products are sold through an international network of B2B partners. ADDITIONAL RESOURCES 1– Link to the video of the 3D rocket launch at the national aquarium here: https://youtu.be/ShfGydxB5D8 2– Link to the report from Goldman Sachs: http://www.goldmansachs.com/our-thinking/pages/technology-driving-innovation-folder/virtual-and-augmented-reality/report.pdf Link to PRESS KIT: https://www.realfiction.com/press  Link to all future information about the product DeepFrame: https://www.realfiction.com/solutions/mixed-reality/deepframe CONTACTFor more information, please contact:Clas DyrholmFounder & CEOMobile: +45 2522 3281E-mail: clas@realfiction.com About Realfiction Founded in Denmark in 2008, Realfiction is a market innovator within mixed-reality solutions, a market estimated to reach USD 80 billion in 2025. Realfiction’s first product, Dreamoc, has since its launch sold over 10.000 units, and the company is now launching its new patent-pending technology DeepFrame, a series of ground-breaking large format mixed-reality screens. DeepFrame offers a wealth of new applications for companies across industries such as entertainment, manufacturing and retail, as well as a broad range of future consumer products.

WannaCry ransomware highlights need for resiliency, advises Cognosec

Some of the code used to programme the worm had previously been utilised for malware distributed by the Lazarus Group – hackers that were also responsible for the 2014 Sony attack which was blamed on North Korea. The Windows vulnerability that had been identified was originally stolen from the NSA by a group of hackers called Shadow Brokers. The attack uses a vulnerability known as EternalBlue, a weakness in the NetBIOS implementation. Microsoft has issued a patch which can be found here: https://blogs.technet.microsoft.com/msrc/2017/05/12/customer-guidance-for-wannacrypt-attacks/ In Britain, hospitals were locked out of their systems. In Germany, railway displays stopped working. Russia was badly affected and China, a booming marketplace for pirated software, was also badly affected. In Spain, the telecom provider Telefonica broke down. A 20-year-old software engineer found the ‘kill switch’ for the software over the weekend. However, as the worm mutated, the switch didn’t stop its distribution for very long. As businesses opened after the weekend and computers were turned on, the worm began spreading further. So far, more than 230,000 computers in over 150 countries were taken out, and numbers are still rising. This once again shows us how vulnerable our digital society is. It is another wakening call for enterprises to take security more serious. On the one hand, the vulnerability was known for several months and many failed to adequately assess the risk they were exposed to and failed to secure their systems. On the other hand, many organisations still operate equipment running on outdated unsupported operating systems. While it is understandable that critical infrastructure hardware is difficult and expensive to replace, modern antimalware systems could have stopped the worm from reaching them. It remains to be seen how long it will take for the affected organisations to return to normal operations. Once again, we will see the importance of resiliency. It is not enough to detect and attempt to contain malware, we also need to focus on restoring our systems as soon as possible once the breach is contained. How well we do this remains to be seen over the next few weeks.

Peter Bergman appointed new General Manager at Boliden Kevitsa

Peter Bergman has been appointed as the new General Manager of Boliden Kevitsa. He will take over on August 15. Peter Bergman has an M.Sc. in Mining Engineering from Luleå University of Technology. He joined Boliden in 2000 and has held several positions within Boliden Mines over the years. Most recently, he was Acting General Manager of Boliden Aitik and before that, the Mine Manager of the Kankberg Mine in the Boliden Area. Peter also knows Kevitsa well, as he was the Project Manager in charge of the integration project when Kevitsa was acquired by Boliden in 2016. “Peter has a strong track record as a leader and is well equipped both to lead the continued development of Kevitsa and to secure its further integration into the Boliden family,” says Mikael Staffas, President Boliden Mines. “I would also like to thank Alan for his very strong leadership during Kevitsa’s recent transition phase.” Alan Delaney, who is the present General Manager at Kevitsa will take up a senior position within First Quantum Minerals.   For further information, please contact: Mikael Staffas, President Boliden Mines, tel: +46 (0)70 921 27 94Klas Nilsson, Director Group Communications, tel: +46 (0)70 453 65 88   Boliden is a metals company with a commitment to sustainable development. Our roots are Nordic, but our business is global. The company’s core competence is within the fields of exploration, mining, smelting and metals recycling. Boliden has a total of approximately 5,500 employees and a turnover of SEK 40 billion. Its share is listed on NASDAQ OMX Stockholm, segment Large Cap.www.boliden.com

Idogen has been granted EUR 2.9 million funding from Horizon 2020

The EU Horizon 2020 SME Instrument phase II grant runs over 33 months and the overall goal of Idogen’s granted application is to perform preclinical safety studies, establish an in-house production capability for manufacture of the tolerogenic vaccine for clinical studies, and perform the first phase I/IIa study in patients with hemophilia A who have inhibitory factor VIII antibodies. The funding will be paid in tranches during the project’s term. “We are very grateful and proud to be one of the few chosen in the tough competition for funding from the Horizon 2020, SME Instrument. The fact that EU chooses to fund our project is an important confirmation of the potential of our vaccine technology.” CEO Lars Hedbys comments. About Horizon 2020 – The EU Framework Programme for Research and Innovation  Horizon 2020 is the biggest EU Research and Innovation programme ever, with nearly 80 billion Euro of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The goal of the programme is to ensure that Europe produces world-class science, removes barriers to innovation, and facilitates for the public and private sectors to work together in delivering innovation. The SME Instrument is aimed at small and medium-sized businesses and allows financing of individual companies. For additional information about Horizon 2020, see https://ec.europa.eu/programmes/horizon2020/. For additional information about Idogen, please contact: Lars Hedbys, CEO Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.com This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 18th of May 2017.

HiQ SUPPORTS THE SWEDISH TEAM IN ICPC

The team Omogen Heap – Simon Lindholm, Mårten Wiman and Johan Sannemo – will represent Sweden in ICPC where 130 teams from all parts of the world will compete for the world title. The teams will compete for five hours, and will be trying hard to solve 10-12 algorithmic problems. The team that solves the most, and do it the quickest, is the winner.“Competitive programming is such a small sport in Sweden compared with in countries like Russia, The US and China. The competition is something that really put our skills to the test, so we are very happy that HiQ share our view that this is important for Swedish programming and hopefully it will make more people interested”, said Simon Lindholm, Mårten Wiman and Johan Sannemo. We will be able to follow Omogen Heap – the name of the team pays tribute to the artist Imogen Heap – during the entire week on Facebook, Instagram and Linkedin. It will all end with a homecoming party at the HiQ office in Stockholm on Friday, 26 May. Magnus Gudéhn, CEO of HiQ Stockholm:“All major Swedish success abroad comes down to a smart, innovative and creative programmer that have done some excellent job. That role will only be more important in the future, and for us its very natural and important to endorse the people that will bring us the next generation of Swedish success stories”, said Magnus Gudéhn. What is the difference between competitive programming and “normal” programming?Omogen Heap explains:“In the competitive programming, we get problems that are solely of mathematical nature. You must figure out an algorithm pretty quickly, for instance find the shortest way between two places in an enormous road network. Those kinds of problems we rarely see in software programming. Unlike in normal programming it’s not crucial that the code is easy to read and maintain.” So how far do you think you can go in the World Championships?“We are a pretty experienced team by now, we all have competed for seven years, so we will really put a lot of trust in our routines.” Further information about the competition:http://icpclive.com          For further information, please contact:Magnus Gudéhn, CEO, HiQ Stockholm, tel: +4670-420 00 82, e-mail: magnus.gudehn@hiq.seErik Ridman, Head of Communications, HiQ, tel: +4670-750 80 60, e-mail: erik.ridman@hiq.se 

All Sectra customers live following recent ransomware attack

“I am proud to say that the close partnership we have with all our customers in combination with clear crisis management processes has made this an efficient, although tough journey. We have worked around the clock, also over the weekend, to get systems back up at record times. As a medical IT company with its roots in cybersecurity, we have a big advantage in situations like these,” says Jane Rendall, Managing Director, Sectra Ltd. Over the weekend of May 12-14, several healthcare organizations in the UK were affected by a ransomware attack. The ransomware delivery campaign spread through a combination of a phishing attack and by exploiting a vulnerability in Microsoft windows operating systems. The ransomware had a major impact in the UK. Sectra is one of the four big imaging IT providers in this area, with more than 50 customers including some of the biggest UK trusts. In addition, more than 400 institutions across the UK are connected to Sectra’s service for transferring images between healthcare providers, patients or medico-legal staff, Sectra Image Exchange Portal (IEP). Sectra was in contact with all customers on Friday May 12 and had, as many other vendors, several systems infected. Sectra's monitoring service provided an overview of the status of most systems and effort could be directed where it was needed the most. Sectra has since Friday, in close co-operation with the healthcare providers themselves, worked to ensure that its customers can begin to operate their systems again. Where needed, infected systems have been rebuilt. The Image Exchange Portal servers are patched with all available security updates at the time of release and were therefore not affected. Sectra will continue to work to support all customers to ensure the security of their systems, following this attack and going forward into the future.

Interim report January 1 - March 31, 2017

RaySearch Laboratories AB (publ) “The positive trend continued in the first quarter and net sales increased 33 percent to SEK 127 M (95), of which revenues from RayStation® rose 39 percent to SEK 112 M (81), and operating profit rose 43 percent to SEK 33 M (23). MD Anderson has become collaboration partner regarding RayCare® and the development work is progressing as planned,” says Johan Löf, President and CEO of RaySearch.  THREE MONTHS (JANUARY-MARCH 2017)  · Net sales SEK 126.8 M (95.4), of which revenues from RayStation SEK 112.3 M (80.8)  · Profit after tax SEK 26.3 M (17.8), and earnings per share before/after dilution SEK 0.77 (0.52)  · Operating profit SEK 33.5 M (23.4)  · Cash flow negative SEK 3.0 M (neg: 5.2)  · Order intake excl. service agreements SEK 104.9 M (81.9), of which RayStation SEK 93.8 M (72.6)  · At the end of the period, order backlog for RayStation was SEK 58.1 M (47.1) SIGNIFICANT EVENTS DURING THE FIRST QUARTER  · RayStation 6 was launched*, making RayStation the only treatment planning system that can create plans for Accuray’s TomoTherapyTM treatment system, in addition to conventional linear accelerators.  · RayStation was chosen by several leading cancer clinics, including Nottingham City Hospital in the UK, Zhuozhou in China, the Tata Memorial Centre in India, Kennestone Hospital (part of WellStar Health System) and Sharp Memorial Hospital (part of Sharp HealthCare) in the US. In addition, among others, the Maryland Proton Treatment Center, in partnership with the University of Maryland, have expanded their RayStation installations.  · The University Health Network (UHN) in Canada has exclusively licensed a new artificial intelligence (AI) technology for automated radiation therapy treatment planning (AutoPlanning) to RaySearch.  · Long-term collaborative agreement with MD Anderson related to RayCare*.  · RaySearch’s CEO and founder, Johan Löf was named Sweden’s foremost entrepreneur in the Swedish final of the EY Entrepreneur of the Year 2016 competition.  * Regulatory clearance required in some markets NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD  ABOUT RAYSEARCHRaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information about RaySearch is available at www.raysearchlabs.com.  FOR FURTHER INFORMATION, PLEASE CONTACT:Johan Löf, President and CEO                  Tel: +46 8 510 530 00           E-mail: johan.lof@raysearchlabs.comPeter Thysell, CFO                                    Tel: +46 70 661 05 59           E-mail: peter.thysell@raysearchlabs.com 

FIRST DAY OF TRADING IN THE MUNTERS SHARE

For the complete press release follow this link: https://www.munters.com/en/media/news/global-news/2017/nasdaq/ For more information: John Peter Leesi, CEO Munters GroupPhone: +46 8 626 63 60 John Womack, Investor RelationsPhone: +46 706 782499 THIS INFORMATION WAS RELEASED FOR PUBLICATION AT 08:00 CET ON MAY 19 2017. About Munters Founded in 1955, Munters is a leading global provider of energy efficient and mission critical precision climate control solutions for commercial and industrial applications. Munters is organised in four business areas: Air Treatment, Data Centers, AgHort and Mist Elimination, and supported by Global Operations and Global Services organisations. Each of these business areas addresses a set of end markets, customer industries and applications, with an offering based on Munters’ technologies and specialist competencies. The Company operates globally with more than 3,500 FTEs working in over 30 countries to provide Munters’ products and solutions to a diverse range of customers, including a wide range of global blue chip companies, in over 180 countries. Today, the Company has a production footprint that includes 18 major manufacturing facilities and seven assembly units across 16 countries worldwide. For the twelve months ended 31 March 2017, net sales grew by 15% period on period to SEK 6,340m, and adjusted EBITA was SEK 808m, corresponding to an adjusted EBITA margin of 12.8%. For more information see www.munters.com About Nordic Capital Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. The Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5bn in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory entities in Sweden, Denmark, Finland, Norway, Germany and the UK. For more information see www.nordiccapital.com

Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017

The details of the poster presentation are as follows: Blockade of Axl with the small molecule inhibitor BGB324 shows activity in vitro and in patients with high-risk MDS. ◦       Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant ◦       Abstract number: 7059 ◦       Monday Jun 5, 2017 8:00 AM - 11:30 AM (CT) Further details can be found at http://abstracts.asco.org/. About MDS MDS refers to a range of conditions that can occur when the blood-forming cells in the bone marrow are damaged, interfering with the making of new blood cells. In about one-third of patients, MDS can progress into AML. Treatment typically consists of supportive therapy and may include bone marrow stimulation, hypomethylating agents and cytotoxic chemotherapy. Existing therapies are particularly inadequate in patients with high risk MDS, who have a median survival of five months. About ASCO From June 2 to June 6 2017, over 30,000 oncology professionals from around the globe will meet in Chicago, IL, to discuss the latest advances in cancer therapy during the 2017 ASCO Annual Meeting, organised by the American Society Of Clinical Oncology (ASCO). About BerGenBio ASA BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of Axl kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers. BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in Phase II clinical development in three major cancer indications. It is the only selective Axl inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with Merck & Co. Inc. (MSD). The Company is also developing a diversified pre-clinical pipeline of selective Axl inhibitors including BGB149, anti-Axl monoclonal antibody. For further information, please visit: www.bergenbio.com KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech.  -Ends- Contacts   Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

CHANGE IN WULFF GROUP PLC’S EXECUTIVE BOARD

STOCK EXCHANGE RELEASE         May 19, 2017 at 9.00 A.M.  Wulff Group Plc’s CFO and Group Executive Board member Elina Rahkonen resigns from her position and transfers to another company at the beginning of August 2017. The search for a new CFO will begin immediately.  Wulff Group Plc’s CEO and Chairman of the Group Executive Board Kimmo Laaksonen, CEO of Wulff Entre Ltd Ninni Arion, Managing Director of Wulff Supplies Ab Trond Fikseaunet, Wulff Group Plc’s Communications and Marketing Director Tarja Törmänen, and Veijo Ågerfalk, Head of Direct Sales Division, will continue in the Group Executive Board.  In Vantaa on May 19, 2017 WULFF GROUP PLCBOARD OF DIRECTORS Further information:CEO Kimmo Laaksonentel. +358 300 870 414 or mobile: +358 50 469 3060e-mail: kimmo.laaksonen@wulff.fi   DISTRIBUTIONNasdaq Helsinki OyKey mediawww.wulff-group.com Wulff Group Plc is the most significant player in office supplies and a domestic and Scandinavian industry pioneer. Wulff enables working in environments where companies and entrepreneurs operate. We offer the industry’s most comprehensive product and service range that can help you create an office wherever you want it. What would you like? We offer our customers office supplies, facility management products, catering solutions, IT supplies, ergonomics, first aid, LED lighting solutions and innovative products for worksites. Customers can also acquire international exhibition services from Wulff. In addition to Finland, Wulff operates in Sweden, Norway, and Denmark. Check out our products and services at Wulff.fi.

Brighter interim information January - March 2017.

The full Interim information will be available in pdf on Brighter's website www.brighter.se within short. The Swedish version in pdf is attached to this press release. January 1 – March 31, 2017.  · Operating income amounted to SEK 7,007 thousand (SEK 5,398 thousand).  · Profit after financial items amounted to SEK -2,981 thousand (-2 948 thousand).  · Earnings per share before dilution SEK -0.57 (SEK -0.07).  · Earnings per share after dilution SEK -0.57 (SEK -0.07).  Significant events January to March 2017.  · 2017-03-28 – The Swedish tax authority raises the valuation of Brighter’s shares in Camanio Care by 60%. · 2017-03-17 – Camanio Care to be listed on AktieTorget. · 2017-02-20 – Brighter signs agreement with Sonat for global logistics solution. · 2017-01-05 – Record date for distribution of shares in Camanio Care to Brighters shareholders has been set. Significant events after the period.  · 2017-05-16 – Brighter selects AIS & Ericsson to launch the diabetes solution Actiste in Thailand. · 2017-05-15 – Brighter subscribes in whole to Camanio Care's rights issue for China expansion. · 2017-05-08 – New record date for the distribution of free warrants. · 2017-05-05 – Change in number of shares in Brighter AB. · 2017-04-26 – Brighter secures external financing of up to SEK 100 million to support the launch of Actiste® and issues free warrants to its shareholders. · 2017-04-25 – Brighter launches actiste.com and demonstrates its unique diabetes service Actiste for the first time at Demo@Vitalis. · 2017-04-04 – Brighter partners with Indonesia Mampu to fight diabetes in Indonesia. For more information, please contact:Truls Sjöstedt, CEO            Tel: +46 709 73 46 00            Email: truls.sjostedt@brighter.se  Henrik Norström, COO            Tel: +46 733 40 30 45            Email: henrik.norstrom@brighter.se About Brighter AB (publ)    Brighter develops healthtech solutions with its data-driven mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on    NASDAQOMX First North/BRIG   .  Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50,    CorporateFinance@remium.com  ,   www.remium.com  .

Diamyd® in combination with etanercept and vitamin D shows safety after six months

When all 20 patients have been followed for 6 months, a preliminary summary analysis shows that the patients’ endogenous insulin secretion, measured as C-peptide Area Under the Curve (AUC nmol/L), on average decreased by 16% and fasting C-peptide decreased by 4%. HbA1c increased on average 3% and the insulin dose increased by 7% for the patient group. The treatment has been safe and tolerable and no serious side effects have been reported. “It is too early to draw any firm conclusions on efficacy after 6 months, but the impression is that the decrease of C-peptide, fasting or stimulated, is somewhat less than we commonly see in placebo-treated diabetic patients in the same age group,” says Professor Johnny Ludvigsson, principal investigator and sponsor of the trial. “Further follow-up is important. ”  “The results at 6 months give some evidence of a possible positive effect, but the patients must be followed for a longer time for us to learn if, and how a similar combination with an immunosuppressive drug can enhance the effect of the diabetes vaccine,” says Ulf Hannelius, CEO of Diamyd Medical. “As announced, preparations are being made to start our own follow-up trial this fall, where the diabetes vaccine Diamyd® is given in the lymph node, based on preliminary results from the DIAGNODE-1 pilot trial that look very promising.” About EDCT IIaThe Phase II trial EDCR IIa (Etanercept-Diamyd®-Combination-Regimen) is being conducted at eight pediatric diabetes clinics in Sweden. The trial is an open label clinical pilot trial in children and adolescents between 8 and 18 years of age, newly diagnosed with type 1 diabetes, in which the diabetes vaccine Diamyd® is combined with two already approved substances, etanercept and vitamin D. The patients will be followed for a total of 30 months. The aim of the study is to evaluate the safety of the combination treatment as well as its impact on the immune system. The trial is the first of its kind, where the diabetes vaccine Diamyd® in combination with etanercept and vitamin D is tested against the complex autoimmune process causing type 1 diabetes. The trial is included in a series of combination trials with the diabetes vaccine Diamyd® aiming to enhance the effect (16%, p=0.1) previously seen in a European Phase III study including 334 newly diagnosed type 1 diabetes patients. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical trials are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

Senzime receives research grants from Green Innovation Park

There is a need to measure the presence of certain substances (such as carbon and nitrogen compounds) in the roots of trees. Roots secrete various compounds that are substrates for microorganisms. In order to monitor the secretion of substances from tree roots, a sample collector must be able to be positioned in close proximity to the target root system, and must avoid sampling of the surrounding environment that may contaminate the results. Senzime’s OnZurf Probe has an "open window" that allows to direct the probe precisely to the measuring area of interest, thus collecting substances from the target area. It is anticipated that the results will be presented by the end of 2017. Senzime’s main focus of monitoring development remains in the medical technology area where the company is expecting the CE marking.   For further information, please contact:  Lena Söderström, CEO of Senzime AB Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com  TO THE EDITORS   About Senzime   Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on NASDAQ First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com   

Cantargia strengthens organisation with CFO

Bengt Jöndell graduated with an M.Sc. in Economics and Business from Lund University and an M.Sc. in Engineering from the Faculty of Engineering at Lund University. Since then he has gained extensive experience mainly in various areas of the pharmaceutical and biotech industries and at other medium-sized companies. His previous positions include various roles in the Pharmacia group and senior financial positions at Inpac AB, Bonesupport AB and BTJ Group. Over the past year he has been Acting CFO at Enzymatica AB. Bengt Jöndell will take up his post at Cantargia on 22 May 2017. “As Cantargia continues to develop a need has arisen to strengthen our management team with a CFO”, Göran Forsberg, CEO of Cantargia, says. “Bengt has a background and skills profile that fit in very well with Cantargia, and we look forward to working with him”. “With my experience from several pharmaceutical-related businesses, it feels very exciting and inspiring to become a part of Cantargia’s organisation”, Bengt Jöndell says.  For further information, please contact  Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 19 May 2017, at 10:15. About Cantargia  Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer. Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

Hydrogen fueling station from Nel opened in Rostock – first to achieve German CEP approval

(Oslo, May 19 2017) Earlier today, H2 MOBILITY Deutschland GmbH & Co.KG inaugurated a hydrogen fueling station in Rostock Germany, delivered by Nel ASA (Nel). The station is the first to achieve approval from the Public-Private Clean Energy Partnership (CEP) in accordance with the latest 2016 version of the SAE J2601 standard. This ensures that vehicle users experience fast and reliable fueling of hydrogen with long driving range, similar to that of gasoline vehicles. “The latest generation H2Station® which we have installed for TOTAL in Rostock, is the result of extensive field-testing of our technology in all environments. It includes innovative, in-house developed solutions, which ensure top performance, according to the latest international standards for fueling stations,” says Bjørn Simonsen, Vice President for Market Development and Public Relations. The Rostock station is the first to achieve CEP approval in accordance with the latest 2016 version of the SAE J2601 standard. Nel Hydrogen was also the first to achieve CEP approval for the earlier 2014 version of the SAE J2601 for a hydrogen station delivered to Shell in Hamburg. The SAE J2601 standard is a global common requirement from the car manufacturers as well as owners of hydrogen stations. The H2Station® technology from Nel Hydrogen therefore underwent extensive acceptance and verification tests and reviews by the major car manufacturers. “To be able to deliver a standard product fully compliant with the global international SAE J2601 standard is great and makes it easier for our station customers to purchase and roll-out H2Stations”, Mr. Simonsen concludes. The station in Rostock adds to the growing hydrogen fueling network currently being deployed by H2 MOBILITY Deutschland in a joint venture between six industrial companies – Air Liquide, Daimler, Linde, OMV, Shell and Total. The action plan for H2MOBILITY envisages a Germany-wide network of hydrogen fueling stations onwards 2023. In addition to the Rostock station, Nel is currently manufacturing two stations for H2 MOBILITY with expected delivery during 2017.  ENDS For additional information, please contact: Jon André Løkke, CEO, +47 907 44 949 Bjørn Simonsen, VP Market Development & PR, +47 971 79 821 About Nel ASA | www.nelhydrogen.com       Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

Waystream is partnering up with the German purchasing organization BREKO for new growth opportunities

BREKO, founded in 2010, consists of 282 member companies with the goal to help broadband operators to find the right supplier for their broadband expansion projects. As a provider of active network equipment Waystream, as well as other suppliers, play an important role in BREKO’s mission to meet the increased need for advanced digital infrastructure. “BREKO EG is always on the lookout for technologies that make it easier for the members of BREKO EG to expand their network operations," says Jürgen Magull, Managing Director of BREKO Einkaufsgemeinschaft. "We are therefore pleased to welcome Waystream as a partner of BREKO EG. Waystream is a specialist in active networking technology and their excellent track record from the Swedish market will be very beneficiary in our work to promote fiber network roll-out in Germany.” “We are pleased to now be a part of BREKO and we hope that this membership will accelerate our expansion in the German market. By a tight cooperation with BREKO we can reach a large part of our target group," says Johnny Hedlund, CEO of Waystream. BREKO EG and Waystream will jointly ensure that the members of BREKO receive the best possible support in their network expansion plans. The joint activities include trade fair appearances, information about innovations and cooperation in working groups. For more information, contact: Joana Castelar, Marketing Manager Waystream Mobile: +46 (0) 737 – 28 12 13 Email: joana.castelar@waystream.com  About Waystream    Waystream sells and designs advanced digital infrastructure including switches and routers. With our products and expertise, we help telecom operators and service providers to offer reliable and user-centric network services with a high level of functionality. Our products are smart, easy to use and manage, and designed to create the best possible experience for the end user. The company is traded on the NASDAQ First North. Waystream’s Certified Adviser is FNCA Sweden AB.

The investigation against Julian Assange is discontinued

– Almost 5 years ago Julian Assange was permitted refuge at the Ecuadorian embassy in London, where he has resided ever since. In doing so, he has escaped all attempts by the Swedish and British authorities to execute the decision to surrender him to Sweden in accordance with the EU rules concerning the European Arrest Warrant. My assessment is that the surrender cannot be executed in the foreseeable future, says Marianne Ny. According to Swedish legislation, a criminal investigation is to be conducted as quickly as possible. At the point when a prosecutor has exhausted the possibilities to continue the investigation, the prosecutor is obliged to discontinue the investigation. – At this point, all possibilities to conduct the investigation are exhausted. In order to proceed with the case, Julian Assange would have to be formally notified of the criminal suspicions against him. We cannot expect to receive assistance from Ecuador regarding this. Therefore the investigation is discontinued. – If he, at a later date, makes himself available, I will be able to decide to resume the investigation immediately, says Marianne Ny. As a result of the decision to discontinue the investigation, the prosecutor has reversed the decision to detain him in his absence and withdrawn the EAW. – In view of the fact that all prospects of pursuing the investigation under present circumstances are exhausted, it appears that it is no longer proportionate to maintain the arrest of Julian Assange in his absence. Consequently, there is no basis upon which to continue the investigation, says Marianne Ny. Translation of the decision  (pdf) Case no. in Stockholm District Court: B 12885-10 Press service+46 10 562 50 20

Lemminkäinen to build a University of Applied Sciences in Turku, Finland

LEMMINKÄINEN CORPORATION        INVESTOR NEWS     19 MAY 2017 AT 2:00 P.M.  LEMMINKÄINEN TO BUILD A UNIVERSITY OF APPLIED SCIENCES IN TURKU, FINLAND  Lemminkäinen and Turku Technology Properties Ltd have signed an agreement on the construction of the Kupittaa campus of Turku University of Applied Sciences in Finland. Construction work will begin in late 2017 and is scheduled to be completed in spring 2020. The parties have agreed not to disclose the value of the agreement.  The building’s gross area is 28,400 square metres. It will house classrooms for individual and collaborative learning, lecture halls and teamwork spaces as well as various laboratory facilities, such as acoustics, power electronics and concrete laboratories. The building will also include office space, shared multipurpose space and premises for a restaurant, sports and parking. Turku University of Applied Sciences will centralise all of its activities in the area of technical education in the new building. The building will be used by approximately 2,000 students and 350 employees. The new building is part of a City of Turku project aimed at increasing the efficiency of operations and centralising University of Applied Sciences education in Kupittaa.   The project will be implemented as a turnkey contract comprising the design of the school as well as its construction to the point where it is ready to use. The construction site is located in the busy Turku Science Park area in the Kupittaa district.   “We chose Lemminkäinen as the contractor due to the company’s strong track record in building versatile, adaptable and technically demanding premises,” says Mikko Lehtinen, CEO of Turku Technology Properties Ltd.    Lemminkäinen is currently also building a new indoor sports centre in Turku. The project will be completed in late 2017.   LEMMINKÄINEN CORPORATION Corporate Communications  ADDITIONAL INFORMATION: Pauli MäkeläExecutive Vice President, Building Construction, FinlandTel. +358 2071 53426pauli.makela@lemminkainen.com  DISTRIBUTION: Key mediawww.lemminkainen.com Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and the 4,700 professionals we employ, we build a sustainable society. In 2016, our net sales were EUR 1.7 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

IdeS selected for EMA Priority Medicines (PRIME) scheme

Göran Arvidson, President and CEO of Hansa Medical, said: “The granting of PRIME access by the EMA allows us to continue to accelerate the development of IdeS. We believe IdeS could be a potentially transformative treatment option for those patients in need of lifesaving kidney transplantation. We would like to thank the EMA for their support and we look forward to working with them to advance this important new drug towards submission of a Market Authorization Application (MAA) for EU marketing authorization.” The PRIME designation for IdeS was granted on the basis of data from four independent Phase II studies in the U.S. and Sweden (ClinicalTrials.gov Identifiers NCT02224820, NCT02426684, NCT02475551 and NCT02790437), the request included data from 30 HLA-sensitized patients, who received IdeS immediately before kidney transplantation. IdeS was shown to be effective in reducing donor specific antibodies (DSAs) to levels allowing lifesaving kidney transplantation. The clinical multicenter study Highdes (NCT02790437) is currently recruiting patients in the U.S. and Europe that have either failed on previous attempts of desensitization or are considered to be too difficult to desensitize with currently available methods. The aims are to complete recruitment of approximately 20 patients during 2017, submit a Biologics License Application (BLA) to the FDA in 2018 in order to get marketing authorization to commercialize IdeS in the U.S. and file Marketing Authorization Application (MAA) at the European Medicines Agency (EMA) for marketing authorization of IdeS in the European market. The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person stated below on May 19, 2017 at 14.00 CEST. 

Invitation to presentation of Sectra’s year-end report on May 30

Publication of year-end report:  8:00 a.m. May 30, 2017 Presentation:  12:00 noon May 30, 2017 Place:  Operaterrassen in Stockholm, Sweden To attend the conference, please submit a notification via: www.financialhearings.com/event/6797 The presentation will be held in English and can also be followed online via: www.sectra.se/irwebcast. A recorded version will be available via this link after the conference. Torbjörn Kronander, Sectra’s President and CEO, and Mats Franzén, Sectra’s CFO, will present the year-end report and answer any subsequent questions. Marie Ekström Trägårdh, Executive Vice President and President of the Imaging IT Solutions business area, will attend to answer any subsequent questions. Sectra’s financial calendar for the coming fiscal year  · September 12, 2017 at 8:00 a.m.:  Three-month interim report            · September 13, 2017 at 3:30 p.m.:  Annual General Meeting 2017       · December 8, 2017 at 8:00 a.m.:  Six-month interim report · March 6, 2018 at 8:00 a.m.:  Nine-month interim report · May 29, 2018 at 8:00 a.m.:  Year-end report 2017/2018                      Further information about Sectra’s financial events and interim reports: http://www.sectra.com/investor/calendar/ Subscribe for information  To subscribe for financial reports, invitations and information from Sectra via e-mail, please fill in your contact information at www.sectra.com/subscribe.  

Safety Review Committee Approves the Continued Evaluation of the 20 MBq/kg Betalutin® with 100 mg/m2 Lilotomab Regimen in Phase 2 Cohort in NHL

Oslo, Norway, 19 May 2017 Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-01 clinical trial of Betalutin® in non-Hodgkin’s Lymphoma (NHL) has reviewed safety data from the study and approved continued clinical evaluation of 20 MBq/kg Betalutin® administered after pre-dosing with 100 mg/m2 lilotomab.Following the SRC’s recommendation, new patients will be enrolled into a Phase 2 expansion cohort of Arm 4 in Betalutin’s Phase 1/2 study LYMRIT 37-01, to continue the collection of safety and efficacy data of 20 MBq/kg Betalutin® after pre-dosing with 100 mg/m2 lilotomab. This will enable the company to build a robust database of clinical data to confirm the optimal dosing regimen for the pivotal Phase 2 PARADIGME study, which is on track to start in the second half of 2017. Luigi Costa, Nordic Nanovector CEO, said: “This recommendation from the SRC represents another important milestone for the development of Betalutin®, in line with our strategy and established timelines. It supports the hypothesis that a higher pre-dosing regimen may enable the use of a higher dose of Betalutin®. The enrolment of new patients in Phase 2 provides the opportunity to collect additional safety and preliminary efficacy data to support the selection of the dosing regimen we will use in PARADIGME later this year.” About LYMRIT 37-01 The LYMRIT 37-01 study is an ongoing Phase 1/2 open label, dose-escalation study with four treatment arms in patients with relapsed NHL to establish the recommended dosing regimen of single-dose Betalutin® for Phase 2. The study is investigating three doses of Betalutin® and different pre-dosing regimens with the aim of identifying an optimal dose regimen to take into a pivotal Phase 2 PARADIGME trial. The most recent results were presented at the American Society of Hematology (ASH) annual meeting in December 2016 and showed: • Significant anti-tumour activity observed: ORR of 62%, CR 38% in Arm 1 patients receiving 15MBq/kg; consistent for 16 patients treated in Arm 1/Phase 2 (ORR 69%, CR 38%)• Durable responses observed: median duration of response of 20.7 months for patients in Arm 1• Well tolerated with a predictable and manageable safety profileUpdated results from LYMRIT 37-01 have been accepted for presentation at the International Conference on Malignant Lymphoma (ICML), June 14-17 in Lugano, Switzerland. For further information, please contact: IR enquiries: Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com Forward-looking statementsThis announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

GBO announces final outcome in the offer for Vigmed

On 27 February 2017, Greiner Bio-One GmbH ("GBO") announced a recommended public offer to the shareholders of Vigmed Holding AB (publ) ("Vigmed") to tender all shares in Vigmed to GBO (the "Offer") for a consideration of SEK 1.00 in cash per share. On 13 April 2017, the Offer consideration was increased to SEK 1.20 in cash per share. On 3 May 2017, GBO declared the Offer unconditional and that the Offer will be completed. The acceptance period expired on 17 May 2017 and, as previously communicated, the acceptance period will not be extended. The shares tendered in the Offer, together with shares that GBO has acquired outside the Offer and the newly issued shares that GBO has subscribed in a directed share issue, amount to in aggregate 61,709,589 shares in Vigmed, corresponding to 84.47 percent of the total number of outstanding shares and votes in Vigmed. At the end of the acceptance period on 17 May 2017, the Offer had been accepted by shareholders representing in total 48,009,383 shares in Vigmed, corresponding to 65.72 percent of the total number of outstanding shares and votes in Vigmed (which would correspond to 73.02 percent of the total number of outstanding shares and votes in Vigmed prior to Vigmed's directed share issue announced on 8 May 2017). GBO has outside the Offer acquired in total 6,394,651 shares in Vigmed, corresponding to 8.75 percent of the total number of outstanding shares and votes in Vigmed. None of these shares have been acquired at a price which exceeds the consideration in the Offer. As a part of supporting Vigmed's need of a capital, GBO has on 7 May 2017 participated in a directed share issue in Vigmed, where GBO subscribed 7,305,555 new shares at a subscription price of SEK 1.10 in cash per share. For further information about the directed share issue, please refer to the press release published by Vigmed on 8 May 2017. Settlement in respect of shares in Vigmed duly tendered in the Offer during the last extension of the acceptance period is expected to be initiated on or about 25 May 2017. Other than the shares in Vigmed acquired as set out above, GBO does not currently own or control any shares or financial instruments that provide a financial exposure equivalent to a holding of shares in Vigmed. GBO might acquire additional shares in Vigmed on the market or through private transactions. "We are pleased to conclude that a significant majority of the shareholders of Vigmed have appreciated GBO's offer and already sold their shares to GBO. As a long-term shareholder GBO is now ready to engage in the challenge of developing Vigmed's business and product portfolio, including to support Vigmed in the significant capital injections that will be required to satisfy Vigmed's need of liquidity in order to realize its long-term prospects", said Rainer Perneker, CEO of the Greiner Bio-One group. Greiner Bio-One GmbH

Telia Company acquires Finnish ICT service company Nebula

Nebula Top Oy was founded in 1997 and offers highly automated and standardized cloud infrastructure services with a strong customer centric model. Nebula’s 145 employees serve a customer base of approximately 44,000 who generate 90 percent subscription-based recurring revenues.  In 2016 Nebula reported net sales of EUR 35.1 million and an adjusted EBITDA of EUR 13.5 million. Based on its 2016 results, the purchase price corresponds to an EV/EBITDA multiple of 12.8x, not considering synergies. Telia Company expects to generate synergies above EUR 10 million within a 3 year period from cross sales as well as production cost savings. In 2018, Telia Company will open one of the largest open data centers in Finland to support digitalization and infrastructure services. “I’m happy to welcome Nebula’s employees and its customers to Telia Company. This is another important step in developing the customer experience by adding a complete portfolio of cost efficient and high level automated services. We are looking forward to working with and learning from Nebula’s very competent staff,” says Johan Dennelind, President and CEO of Telia Company. The acquisition of Nebula Top Oy from the main owner Ratos and other minority owners is subject to approval from the Finnish Competition and Consumer Authority and is expected to be completed in the third quarter of 2017. Following a successful rebranding in March 2017, Telia continues to develop and improve its services to the Finnish customers. For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany .   Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Telia Company.   We’re Telia Company, the New Generation Telco. Our 21,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com.  

TalkPool increases its order intake from large European telecom operators

“TalkPool’s order intake from clients in Europe increased in the second half of 2016 and has continued to accelerate during the first four months of 2017 while order levels from clients in Africa and the Americas have remained stable. Europe generated almost a third of TalkPool’s overall orders in the first four months of 2017”, comments Erik Strömstedt CEO of Talkpool.During the period January to April 2017, approximately 26% of Talkpool revenues relates to the African market and originates from many countries, whereas the 42% of the total revenues relates to the Americas and stems from only two markets.Network services order volumes from Digicel in the Carribbean have remained unchanged during many years but its share has reduced to 37%, down from over 50% a year ago, as business from other clients is growing. Orders from China-based equipment vendor Huawei continue to increase while the share of orders from Swedish Ericsson, with whom TalkPool has a close relation, is continuing to decline.TalkPool continues to get a wide range of IoT orders but the order volumes are still modest.This information is information that TalkPool is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 22 May, 2017.For more information, please contact:Erik Strömstedt, CEO of TalkPool, erik.stromstedt@talkpool.com, Tel: +41 81 250 2020About TalkpoolTalkPool builds, maintains and improves telecommunication networks globally. Through its cutting-edge technical expertise, long experience and agile business model, TalkPool offers global telecom vendors and operators high-quality services on short notice no matter the location. Moreover, TalkPool is one of few companies with actual solutions and contracts in place in the exciting IoT-market. Remium Nordic AB is TalkPool’s Certified Advisor for Nasdaq First North.

SUMMARY FROM ANNUAL GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

The income statements and the balance sheets for the Company and the group were approved and the Board of Directors and the Managing Director were discharged from liability for the financial year 2016. The Meeting resolved to allocate the result in accordance with the proposal of the Board of Directors in the Annual Report. In accordance with the proposal by the Nomination Committee (i) Dennis Stripe, Saeid Esmaeilzadeh, Wilder Fulford, Christian Krüeger and Leif Ryd were re-elected as members of the Board of Directors, (ii) Laura Shunk was elected as new member of the Board of Directors, and (iii) Dennis Stripe was re-elected as Chairman of the Board of Directors. In accordance with the proposal by Nomination Committee, the Meeting resolved that total fees of SEK 1,100,000 are to be paid to the Board of Directors, of which SEK 400,000 to the Chairman of the Board of Directors, SEK 200,000 to each of Wilder Fulford and Laura Shunk and SEK 100,000 to each of Saeid Esmaeilzadeh, Leif Ryd and Christian Krüeger. No fees are to be paid for committee work. The registered accounting firm KPMG AB was re-elected as the auditor of the Company, with the authorised public accountant Duane Swanson as the auditor in charge. The auditors’ fee shall be paid upon approval of their invoice. The Meeting approved the Nomination Committee’s proposal for Nomination Committee and nomination procedure for the Annual General Meeting 2018. The Meeting approved the Board of Directors’ proposal regarding guidelines for remuneration to senior executives. In accordance with the proposal by the Board of Directors, the Meeting resolved on (i) adoption of an employee stock option and warrant programme, (ii) an issue of warrants of series 2017/2020(A), and (iii) an issue of warrants of series 2017/2020(B) and approval of transfers of warrants of series 2017/2020(B). The rationale for the employee stock option and warrant programme is to achieve optimum alignment of interests between the employees and the shareholders in the Company, to create conditions for retaining and recruiting competent personnel to the Episurf group and to drive performance among the employees. The employee stock option and warrant programme includes all employees in the group and comprises no more than 117,400 warrants of series 2017/2020(A) and no more than 513,700 employee stock options (which are hedged by an issue of the same number of warrants of series 2017/2020(B) to the subsidiary Episurf Operations AB). The warrants of series 2017/2020(A) shall be allocated to the participants in the programme for a price of SEK 0,95 (corresponding to the market value) in accordance with the following: (i) the acting CEO is entitled to subscribe for up to 15,000 warrants; (ii) the other four members of the senior management are entitled to subscribe for 8,000 warrants each; and (iii) the other 22 participants are entitled to subscribe for 3,200 warrants each. The employee stock options shall be allocated in accordance with the following: Each participant is proposed to be allotted, free of charge: (i) 6,000 employee stock options (except the acting CEO, who is allotted 10,000 employee stock options), plus (ii) 350 employee stock options per month he or she has been employed by the group, plus (iii) one employee stock options for each warrant subscribed for. Provided that the holder is still employed by the group at the exercise of the options, each employee stock option entitles the employee to purchase one share of series B in the Company during the period 1 June 2020 – 31 May 2021 for a price of SEK 8,55, corresponding to 130 per cent of the average volume weighted share price for the Company’s share of series B on Nasdaq Stockholm during the period from and including 15 May 2017 until and including 19 May 2017. Each warrants of series 2017/2020(A) entitles its holder to subscribe for one share of series B in the Company during the period 1 June 2020 – 31 May 2021 for a price of SEK 8,55. The programme implies that a maximum of 631,100 shares of series B may be issued, corresponding to a maximum dilution of 2.0 per cent of the share capital and 1.4 per cent of the votes in the Company. The employee stock options will be recorded as a personnel expense in the income statement during the vesting period. The total costs for the employee stock options are expected to amount to SEK 0.7 million during the term of the programme. Finally, the Meeting resolved to authorise the Board of Directors to, at one or several occasions until the next Annual General Meeting, resolve on new issues of shares. Episurf Medical AB (publ) The Board of Directors  For more information, please contact: Pål Ryfors, acting CEO, Episurf Medical  Tel: +46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 19.30 CET on 22 May 2017.

BAKKAFROST: Operational EBIT of DKK 335 million for the first quarter of 2017

The Bakkafrost Group delivered a total operating EBIT of DKK 335.5 mil­lion in Q1 2017. Harvested volumes were 13.2 thousand tonnes gutted weight. The combined farming and VAP segments made an operational EBIT of DKK 320.2 million. The farming segment made an operational EBIT of DKK 373.2 million. The salmon spot prices continued in Q1 2017 on a high level from 2016, which was positive for the farming segment. The VAP segment realized higher prices, but is not matched by the high spot prices, and therefore the VAP segment had negative margins in Q1 2017. The VAP segment made an operational EBIT of DKK -53.0 mil­lion. The EBITDA for the FOF segment was DKK 45.1 million. The total volumes harvested in Q1 2017 were 13.2 thousand tonnes gutted weight. Bakkafrost trans­ferred 1.4 million smolts in Q1 2017. In Q1 2017, Havsbrún sourced 106.6 thousand tonnes of raw material. The farming segment made an operational EBIT of DKK 373.2 million for Q1 2017, which corresponds to NOK 34.27 per kg. The VAP segment made an operational EBIT of DKK -53.0 million for Q1 2017. Although the sales prices in the VAP segment have increased, the VAP segment continued to have negative results, primarily due to the high salmon spot prices. The new VAP factory at Glyvrar started production in January 2017, and Q1 2017 was the first quarter when both the harvest operation and the VAP production operated in the combined VAP/harvest factory at Glyvrar. Simultaneously, the old VAP factories were closed. The combined farming and VAP segments made an operational EBIT of DKK 320.2 million for Q1 2017, which corresponds to NOK 29.40 per kg. The FOF segment (fishmeal, oil and feed) made an operational EBITDA of DKK 45.1 million for Q1 2017. Commenting on the result, CEO Regin Jacobsen said: “The first quarter of 2017 was an eventful quarter for Bakkafrost in many ways. In January, Bakkafrost started the VAP production in the new combined harvest/VAP factory at Glyvrar, which was the last of three operations to start up at the premises at Glyvrar since 2014. The two previous are the packaging operation and the harvest operation, which started up in 2014 and 2016 respectively. There were challenges in the farming operation in this quarter, as ISA-virus was confirmed on one farming site. Since ISA suspicion arose in July 2016, Bakkafrost has monitored the development at the farming site closely together with the authorities. Timely action has been taken and all fish harvested immediately.” Bakkafrost’s farming site A-73 Hvannasund Norður has been under suspicion of pathogenic ISA-virus since July 2016. The suspicion rose anew in January 2017, and Bakkafrost decided to harvest the two cages, related to the suspicion. Medio March 2017, Bakkafrost decided to harvest the whole site early as a precautionary action. At the end of March 2017, pathogenic ISA-virus at farming site A-73 Hvanna-sund Norður was confirmed. Bakkafrost decided to accelerate the already started harvest. The harvest of farming site A-73 Hvannasund Norður ended on 12 April 2017, and the average size of the harvested fish was just below 3 kg gutted weight. The Bakkafrost Group’s net interest bearing debt amounted to DKK 458.6 million at the end of Q1 2017. Bakkafrost had undrawn credit facilities of approximately DKK 826.4 million at the end of Q1 2017 and the equity ratio was 65% at 31 March 2017. OUTLOOK Market The salmon market has for the last year or so been affected by decline in supply. The main factors behind this were the harmful algal bloom in Chile in February 2016 and the biological issues in Norway. The negative effect of the Chilean algal bloom on supply of salmon continued into Q1 2017. Expecta­tions are that global supply of Atlantic salmon will shift from reduced supply into growth of supply in Q2 2017. The latest update from Kontali Analyse estimates a global supply of Atlantic salmon to in­crease around 2% in 2017, compared to -6% in 2016. The market place is one of Bakkafrost’s most significant risk areas. Bakkafrost has a geographical and a market price approach. These approaches reduce the exposure to the market risk. To diversify the geographical market risk, Bakkafrost sells its products to all the largest salmon markets in the world, USA, the Far East, Europe and Russia. Farming The outlook for the farming segment is good. The estimates for harvesting volumes and smolt releases are dependent on the biological development. The biological situation is Bakkafrost’s most important risk area. The confirmed presence of patho­genic ISA-virus at farming site A-73 in March, draws attention to the importance of a high quality veter­inary system to reduce the biological risk. Harvest of the fish at farming site A-73 was finished on 12th April 2017, and the site is now in fallow. Bakkafrost focuses on biological risk continuously and has made several new investments and procedures to diminish this risk. The investments in producing larger smolts will gradually reduce the time needed in the fjords to farm the salmon. This is expected to reduce biological risk and increase the capacity. The capacity growth from this investment program will appear in harvested volumes gradually until 2021. Bakkafrost expects to harvest 53,500 tonnes gutted weight in 2017. Bakkafrost expects to release 11.5 million smolts in 2017, compared with 11.7 million smolts in 2016 and 11.3 million smolts released in 2015 – smolts released by Faroe Farming before becoming part of the Bakkafrost Group are included. The number of smolts released is a key element of predicting Bakka­frost’s future production. Sea lice is an area, which has demanded much effort and is a part of the biological risk. The new Faro­ese regulations on sea lice control, which aim at reducing the number of sea lice even further, is ex­pected to increase the operational costs for farming salmon in the Faroe Islands. Bakkafrost focuses on using non-chemical methods in treatments against sea lice. Bakkafrost’s live fish carrier M/S Hans á Bakka has carried out freshwater treatment against sea lice since Q4 2015. In Q4 2016, Bakkafrost invested in a service vessel, M/S Martin, which will primarily use lukewarm sea­water treatment against sea lice. M/S Martin started operation in Q1 2017. In addition to M/S Martin, Bakkafrost invested in another service vessel, M/S Róland, in Q1 2017. M/S Róland is equipped with the same system as M/S Martin and is expected to start operation in June/July 2017. Furthermore, Bakkafrost will increase the use of lumpfish in farming significantly in 2017. VAP (Value added products) Bakkafrost has signed contracts covering around 39% of the expected harvested volumes for the rest of 2017. VAP contracts are at fixed prices, based on the salmon forward prices at the time they are agreed and the expectations for the salmon spot price for the contract period. The contracts last for 6 to 12 months. The long-term strategy is selling around 40-50% of the harvested volumes of salmon as VAP products at fixed price contracts. Selling the products at fixed prices reduces the financial risk with fluctuating salmon prices. The market price for contracted VAP products follows a more stable pattern instead of short-term fluctuations as in the spot market. The price level on long-term contracts are on a higher level than ever before, there are, however, no indications that this price level should decrease significantly. FOF (Fishmeal, -oil and feed) The outlook for the production of fishmeal and fish oil is dependent on the availability of raw material. The ICES 2017 recommendation for blue whiting is 1,342 thousand tonnes, compared with 776 thou­sand tonnes in 2016. Recommendations for herring and mackerel quotas have increased as well. The forecast for production of fishmeal and fish oil is positive and will most likely increase due to higher quotas and better availability. The major market for Havsbrún´s fish feed is the local Faroese market including Bakkafrost’s internal use of fish feed. Havsbrún’s sales of fish feed in 2017 are expected to be at 85,000 tonnes. Investments In June 2016, Bakkafrost announced a five-year investment plan from 2016 to 2020. The total invest-ments for the period are DKK 2.2 billion, including maintenance CAPEX. Investments of around DKK 100 million in the two service vessels, M/S Martin and M/S Róland during 2017, are not included in the investment plan. The purpose of the investment plan is to continue to have one of the most cost conscious value chains in the farming industry, to carry out organic growth, increase flexibility and reduce the biological risk to meet the future consumers’ trends and to be more end-customer orientated. Bakkafrost aims at being self-supplied with smolts at a size of 500g each. The benefits are a shorter production time at sea as well as reduced biological risk. To reach this goal, approximately half of Bakkafrost’s total investments over the next five years will be in hatcheries. Both the harvest operation and the VAP production in the new harvest/VAP factory at Glyvrar are operating. The harvest operation started in the summer of 2016, and the VAP production started in Q1 2017. The old harvest factories in Klaksvík, Kollafjørður and Strendur are closed, as well as the old VAP factories in Fuglafjørður and Glyvrar. There are some extra costs during the start-up period, but the investment is expected to result in operational savings of DKK 70-90 million per year with gradual effect from 2017. Bakkafrost plans to increase the value of offcuts from salmon harvested and processed in the new harvest/-VAP factory. In 2017, Bakkafrost will invest in a new salmon meal and salmon oil plant, lo­cated in Fuglafjørður and operated by Havsbrún. The new salmon meal and salmon oil plant is ex­pected to start operation in late 2017 and is expected to have positive margins in 2018. The FOF seg­ment will also invest in a new feed line, which will increase the capacity of the feed production. Free cash flow from operations, existing financing facilities and partly new financing if advantageous will finance the investments. The dividend policy will be unchanged. Financial Improved market balances in the world market for salmon products and cost conscious production will likely improve the financial flexibility going forward. A high equity ratio together with Bakkafrost’s bank and bond financing makes Bakkafrost’s financial situation strong. This enables Bakkafrost to carry out its investment plans to further focus on strengthening the Group, M&A’s, organic growth oppor­tunities and fulfil its dividend policy in the future. Please find enclosed the Company’s Q1 2017 report and presentation. Contacts: Regin Jacobsen, CEO of P/F Bakkafrost: +298 235001 (mobile) Gunnar Nielsen, CFO of P/F Bakkafrost: +298 235060 (mobile) This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. About Bakkafrost: Bakkafrost is the largest salmon farmer in the Faroe Islands. The Group is fully integrated from feed production to smolt, farming, VAP and sales. The Group has production of fishmeal, fish oil and salmon feed in Fuglafjørður. The Group has primary processing in Glyvrar and Vágur, and secondary pro­cessing (VAP) in Glyvrar. The Group operates sea farming in Norðoyggjar, Eysturoy, Streymoy and Suðuroy. The headquarter is located in Glyvrar, and the company has 820 fulltime employees. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended. Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada or Japan. 2017-Q1 Presentation     Q1 2017 Condenced Interim Consolidated Accounts 

Catena Media acquires casino affiliate Newcasinos.com

Newcasinos.com  is a fast-growing casino affiliate, specialising in reviewing and rating new online casinos. The business was launched in 2015 with the aim to update casino players with the latest trends and news. New Casinos’ markets are mainly UK as well as Sweden and Norway and through its niche focus the acquisition will provide Catena Media with an opportunity for product segmentation. The acquired assets are expected to generate quarterly sales of about EUR 550.000 with an operating margin of around 80 percent. The underlying UK market is currently growing quickly, further strengthening Catena Media’s position in regulated markets. The transfer of the assets and payment is scheduled to take place no later than the 15thof July 2017. The purchase price amounts to an upfront payment of EUR 7.650.000, which is being paid as a cash consideration in conjunction with the transfer of the assets. In addition, there is an earn-out of maximum EUR 4.250.000, which is based on revenue performance over a period of 12 months. In a reasonably expected scenario with a total earn-out purchase price of EUR 3.25 million, the seller needs to generate revenue growth between 25 and 50 percent during the period. “Catena Media has been in the forefront of the consolidation in the affiliate market and wants to keep a leading role. The company is predominantly focusing on larger assets since we are well positioned to capitalize on our size and growth. With this acquisition we are acquiring another successful online casino affiliate to complement and strengthen our portfolio. The sellers have demonstrated a solid growth and an interesting content offering. This is fully in line with our strategy of partly growing through acquisitions and continuing our solid growth story”, says Robert Andersson, CEO of Catena Media. For further information, please contact:   Robert Andersson, CEO Phone: +356 770 329 28 E-mail: robert@catenamedia.comwww.catenamedia.com  The information was submitted for publication, through the agency of the contact person set out above on May 23, 2017 at 09.00 CET About Catena Media  Catena Media is a fast-growing online performance marketing and lead generation company within iGaming with portals like AskGamblers  and RightCasino . The Group has established a leading market position through strong organic growth and acquisitions in its core markets. Catena Media was listed on Nasdaq Stockholm First North Premier in February 2016. By the end of 2016, the company’s revenues reached more than EUR 40 million on a yearly basis. The Group was founded in 2012 and has today about 230 employees. The Group Head Office is situated in Malta. The company’s certified advisor is Avanza. About Newcasinos.com Please visit:www.newcasinos.com/online-2017/www.new-casinos.uk/online-2017/